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      The emergence of HIV strains that are resistant to current HIV protease inhibitors in 
the past few years has become a major concern in AIDS treatment. The goal of this 
project is to design a combinatorial library of potential lead compounds that can bind to 
both the wild-type and mutant proteases and that can resist further mutations. A recent 
crystallographic study of complexes of HIV protease with its substrates has provided 
structural insights into the differential recognition of the substrates and inhibitors.  It has 
been proposed that clinical resistance is a consequence of inhibitors failure to stay within 
the consensus substrate volume. In this work, we devised a quantitative indicator of the 
degree to which a candidate ligand falls outside the consensus substrate volume, and 
determined its correlation with the inhibitor’s sensitivity to clinically relevant resistant 
mutations. The validation of this hypothesis has encouraged us to use this strategy in our 
design of a combinatorial library of inhibitors. 
The compounds in a typical combinatorial library are built around a common structural 
scaffold possessing multiple connection points where substituents can be added by 
reliable synthetic steps. As the number of compounds encompassed by such a 
combinatorial scheme frequently exceeds what can actually be synthesized and tested, 
virtual screening methods are sought to shortlist the compounds. Even though these 
methods require only seconds to minutes of CPU time per compound, exhaustive 
screening of an entire virtual combinatorial library is computationally demanding. We 
therefore implemented a simple algorithm of combining substituents that have been 
optimized independently for the substituent sites. This method was compared with 
Genetic Algorithm, a global optimization method and was found equally efficient. This 
simple method was hence chosen for the design process. 
A combinatorial library based on these ideas and methods has been synthesized and 
tested. It includes four compounds with nanomolar inhibition constants. Two of them 
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Chapter 1. Introduction 
1.1 AIDS and HIV 
1.1.1 AIDS epidemiology 
Acquired Immunodeficiency Syndrome (AIDS) is a severe, immune deficiency syndrome 
due to impaired T-cell function, which results in serious opportunistic infections such as 
tuberculosis, kaposi sarcoma and herpes (1). The UNAIDS reported in 2005 that there are 
about 38 million people worldwide affected by AIDS. Just last year, about 3 million 
people lost their lives to this disease (2).  In 2005, at the G8 nations meeting and the 
United Nations World Summit, world leaders recognized AIDS as a major epidemic and 
committed to provide universal access to AIDS treatment for all who need it (2). 
1.1.2 AIDS infection 
In 1984, a cytocidal retrovirus was identified as an infectious etiologic agent for AIDS 
(3). This virus was named the Human Immunodeficiency Virus (HIV) by the 
International Committee on Taxonomy of Viruses in 1986. AIDS is a communicable 
disease which is transmitted through direct contact of a mucous membrane with a bodily 
fluid of an HIV infected person, such as blood, semen, or vaginal fluid. The main routes 
of HIV transmission are transfusion of blood and blood products, sexual contact, 
transmission from mother to child, and the use of contaminated hypodermic needles. 
Upon infection, HIV attacks host helper T-cells and macrophages, which are major 
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components of the host immune system.  The virus gains entry into the host cell through 
the cell surface receptors CD4 (cluster of differentiation) (4) and co-receptors such as the 
cytokine receptor CCR5 (5). Once inside the cell, HIV disrupts the normal cellular 
function by hijacking the cellular machinery to produce viral proteins. It also affects the 
integrity of the host cell by copious budding during its replication. This eventually leads 
to the destruction of helper T-cells and macrophages. There is an initial decline in the 
count of helper T-cells, which is followed by a short term recovery to a nearly normal 
level. After this recovery, there is an average annual loss of about 60 T-cells/µl. When 
the count falls below 200/µl (the normal count is between 800-1200/µl), the patient is 
diagnosed with AIDS (6). The time period between the recovery and this state 
corresponds to clinical latency. 
The symptoms of acute HIV infection include headache, sore throat, muscle pain and 
other virus-like symptoms. Non-pruritic macular erythematous rashes of the trunk and 
extremities can distinguish HIV from other infectious diseases. During this acute 
infection phase, there is a high level of infectious viruses with heterogeneity in strains in 
the blood, which can be detected by Enzyme Linked Immunosorbent Assay (ELISA) 
detection kits. After the acute phase, patients can be asymptomatic for years. Because of 
the latency involved in the clinical manifestation of this syndrome, the virus was 
classified as lentivirus, a sub-family of retrovirus (7).  
When the helper T-cell count drops below 200/µl, the patient becomes highly susceptible 
to opportunistic infections (OIs). Because of the highly compromised immune system, 
the individual becomes susceptible to a wide range of opportunistic pathogens, which are 
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harmless to the normal population. Candidiasis, Kaposi sarcoma, herpes and 
cytomegalovirus are relatively common OIs among AIDS patients. Neoplasms and 
neurological symptoms such as aseptic meningitis, myelopathies are also not rare in 
AIDS patients (7). The OIs are chiefly responsible for the morbidity and mortality in 
AIDS. 
1.1.3 HIV structure 
The HIV virion is roughly spherical, with a diameter of approximately 100nm. The 
surface is made up of a lipid bilayer and envelope glycoproteins, which occur as trimers 
or tetramers. These glycoproteins include the external surface envelope protein gp120, 
and a trans-membrane protein, gp41, which interact covalently with each other. Gp120 
has binding sites for the host cellular receptors. Beneath the lipid bilayer, there is a viral 
membrane, whose inner structure is supported by a myristoylated matrix protein. This 
protein is important for the viral structure and hence for the integrity of the virion. Apart 
from structural stability, the matrix protein has also been shown to play an important role 
in the incorporation of envelope proteins gp120 and gp41 into the mature virion. Inside 
the virus, there is a cone shaped core structure termed the capsid or nucleoid, which is 
composed of a capsid protein. The nucleoid contains two identical RNA strands and the 
associated proteins viral RNA dependent DNA polymerase and nucleocapsid protein (7) . 













Figure 1.1: Structure of HIV. 
Important structural features are highlighted. Reprinted from (7). 
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1.1.4 The life cycle of HIV 
The life cycle of HIV starts with the attachment of viral particles to the target host cells, 
which are mainly helper T-cells and macrophages. Gp120 aids in the attachment of HIV 
to the host cell by interacting with its cell surface protein CD4. This interaction leads to a 
conformational change in the envelope protein, by which the virus gains entry into the 
host cell. During the process of entry, gp120 is displaced and cleaved by cellular 
proteases, exposing gp41 fusion domain, which has been suggested to be important in 
viral envelope shedding and cleavage. Alternative sites for viral entry through 
complement and Fc receptors have also been proposed (7). After the shedding and 
cleavage of the viral envelope, ribonucleocapsid is released into the host cell. The viral 
RNA undergoes reverse transcription, using its associated RNA-dependent DNA 
polymerase and RNase H proteins, forming double stranded DNA. This viral DNA then 
migrates to the nucleus and integrates with the host chromosomes. Some of the earliest 
mRNA species have regulatory genes, particularly tat, rev and nef. These genes 
determine the state of HIV virus as dormant or active. The primary full length viral 
mRNA is translated into Gag, Pol and Env polyproteins. This early transcription relies 
primarily on the cellular transcription factors. Hence the state of the host cell 
(differentiation or quiescent phase) affects the viral replication cycle. The Gag precursor 
protein on cleavage yields smaller structural proteins p25, p17, p9 and p6, whereas the 
Pol yields functional proteins reverse transcriptase, protease and integrase and Env yields 
two envelope proteins gp120 and gp41. Other viral proteins are produced by alternate 
splicing events. Viral genomic RNA is then incorporated into a capsid forming at the host 
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cell surface. The processing of Gag, Pol and Env polyproteins by HIV protease occurs at 
the cell surface or in budding virion. Viral envelope proteins get inserted on the viral cell 
surface. HIV then buds off the host cell, completing the HIV replication cycle. A cartoon 
representation of HIV life cycle is shown in Figure 1.2. There are several life stages in 
HIV replication cycle that can be considered as targets for anti-AIDS therapy. They are 
viral entry, reverse transcription of viral RNA, integration of viral DNA into host DNA, 
processing of Gag, Pol, Env polyproteins, viral assembly and budding. Gp41 (needed for 
viral fusion), reverse transcriptase and HIV protease are the targets for the existing FDA 

































Figure 1.2: Diagram of the life cycle of HIV. 
 (1) Viral entry and fusion. (2) Envelope shedding and cleavage. (3) Reverse 
transcription. (4) Integration. (5) Cellular transcription and translation. (6) Post 




1.1.5 Anti-HIV therapy 
The four major therapeutic classes of anti-HIV drugs include are nucleoside analogues of 
reverse transcriptase inhibitors (NRTI), non-nucleoside reverse transcriptase inhibitors 
(NNRTI), protease inhibitors (PI) and fusion inhibitors. The first two classes act by 
inhibiting the RNA-dependent DNA polymerase (reverse transcriptase): the NRTIs 
competitively inhibits the binding of nucleosides to reverse transcriptase and thereby 
prevents elongation of viral DNA strand, while the NNRTIs non-competitively inhibit the 
viral reverse transcriptase.  FDA approved NRTIs include Zidovudine (8), Didanosine (9) 
and Lamivudine (10), Zalcitabine (11), Stavudine (12) and Abacavir (13).   Combinations 
of two or more NRTIs such as Combivir (Lamivudine & Zidovudine) and Trizivir 
(Abacavir & Lamivudine & Zidovudine) are also therapeutically used.  Nevirapine (14), 
Delavirdine (15) and Efavirenz (16) are the NNRTIs that are FDA approved.  Protease 
inhibitors act by competitively inhibiting HIV protease, an enzyme that is essential for 
virulence. Amprenavir (17), Indinavir (18), Saquinavir (19), Nelfinavir (20), Ritonavir 
(21), Lopinavir (22) and Atazanavir (23) are FDA approved PIs.  A combination of 
Lopinavir and Ritonavir is also in clinical use.  Fusion inhibitors act by binding to viral 
protein gp41, which is important for the viral entry and fusion. Enfuvirtide (24) is the 
only FDA approved drug that belongs to this class. It is advocated only as an add-on 
drug.  
A combination of one PI or one NNRTI and two NRTIsis routinely used in AIDS therapy 
to overcome the emergence of drug resistant mutations. Such combination therapy, 
termed Highly Active Anti Retroviral Therapy (HAART), has been reported to be 
 8
responsible for a rapid decline in the morbidity and mortality rate associated with HIV 
infection (25). 
1.1.6 HIV protease 
1.1.6.1 Structure 
HIV protease is an enzyme that processes the precursor polyproteins into mature proteins. 
This posttranslational processing is one of the vital processes of the HIV replication 
cycle. Mutation of catalytic Asp25 in HIV protease to asparagine destroys the enzyme’s 
catalytic activity, supporting its classification as an aspartyl protease, a class that also 
includes renin and pepsin. The virion produced by such mutants lacks virulence and 
infectivity (26). A synthetic peptide resembling an HIV protease substrate but with a non-
hydrolysable replacement of the scissile amide bond was found to inhibit HIV protease 
activity. It was also found to inhibit the viral replication in blood lymphocytes. These 
studies suggested that HIV protease could be a suitable target for therapeutic intervention 
(27-29). 
HIV protease shares sequence homology around the active site with other retroviral 
proteases. It is a homodimer, with 99 amino acids in each monomer. It exhibits C2 
symmetry in the absence of ligands. A cartoon representation of HIV protease is given in 
Figure 1.3. The amino and carboxyl termini from both monomers form a four-stranded 
anti-parallel beta sheet at the dimer interface. This structure is stabilized by ionic 
interactions between the N- termini (residues 1-4 of beta strand a) of each monomer and 
the C-termini (residues 96 –99 of beta strand q) of other monomer (30). The beta strand b 
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(residues 9-15) continues to another beta strand c, through a loop, which terminates in the 
active site triad. The catalytic triad Asp (25, 25’), Thr (26,26’), Gly (27,27’) is located at 
the bottom of the dimer interface. Each monomer contributes one aspartic acid to the 
catalytic triad. Coplanar arrangement of catalytic aspartates is due to the network of 
hydrogen bonds resembling “fireman’s grip”, between the loops bearing catalytic triad. 
Thr26 and Thr24 from both the monomers are involved in this network of hydrogen 
bonds. Beta chain d (residues 30-35) which follows the strand c, is terminated at a 
distorted loop (residues 36-42). There is an approximate two fold intra-molecular 
symmetry in the monomer, making second half of the molecule topologically similar to 
the first half of the molecule. The a’ beta strand (resides 43 - 49) and a part (residues 52-
58) of longer b’ beta strand (residues 52-66) form a flap. These glycine rich flap regions, 
from both the monomers, cover the active site. The beta chain c’ (residues 69-78) is 
connected to another beta chain d’ (residues 83-85), through a loop (residues 79-82). A 
well-defined helix (residues 86-94) follows the beta strand d’, which is in turn followed 
by the C-terminal beta strand q. Aψ-shaped beta sheet in the molecular core, is formed by 
four of the beta strands (c, d and d’ ; c’,d and d’). This feature is a characteristic for the 
family of aspartic proteases(31).  
There are at least three distinct subsites on either side of the catalytic triad. The 
numbering of sub sites begins from the catalytic site and continues on either side (Figure 
1.4). The residues that comprise S1 and S1’ site are mostly hydrophobic. Most of the 
crystal structures of inhibitors and substrates show hydrophobic moieties interacting with 
this subsite, though exceptions are not rare (31). Subsites S2 and S2’ are also hydrophobic 
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but still accommodate both hydrophobic and hydrophilic residues (31). The distal 












Figure 1.3: A cartoon representation of HIV protease. 
Substructures are labeled as described in the text. Catalytic aspartates are represented in 














Figure 1.4: Hydrogen bonds between HIV-1 Protease and a modeled substrate. 
Reprinted from (32). 
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1.1.6.2 Substrate recognition 
HIV protease processes Gag, Pol and Env polyprotein into structural and functional 
proteins. These substrates require a large-scale flap opening in HIV protease to access the 
active site. This movement in the flap region can be observed in structures of ligand 
bound and free HIV proteases with more heterogeneous flap structures in the Protein 
Data Bank (PDB) (33), varying from closed to open form. The nature of this movement 
in flap regions is debatable. Some studies have modeled it as rigid lever movement (34), 
while others have described it as a curling of flap tips (35).  
The binding, cleavage, and release of substrates involve large-scale movement of certain 
regions in HIV protease (36, 37). The protease molecule can be conceptually divided into 
four regions based on their mobility (Figure 1.5). They are the fulcrum (residues 11-21 
and 11’-21’), fireman’s grip (residues 22-28 and 22’-28’), flaps (residues 34-59 and 34’-
59’) and cantilever (residues 64-74 and 64’-74’) (Figure 5). The fireman’s grip region is 
considered rigid because of the extensive hydrogen-bond network in this region. 
Movements of the flap, fulcrum and cantilever regions was observed to correlate with 
each other and with the movement of substrates in a recent study using Molecular 
Dynamics (MD) simulations (36). 
Substrates bound to the protease form a parallel β-sheet with one monomer and anti-
parallel β-sheet with the other. The transition between these two parts of the substrate 
generates a kink in the substrate at the center of the active site, directly above the 
catalytic aspartates, which is thought to facilitate cleavage (38). The hydrogen bonds 
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between the substrate and the backbone amide nitrogen of residues I50 through the flap 
water are thought to be important for the catalytic action (39). These hydrogen bonds 
were suggested to exert strain on the scissile amide bond by causing it to rotate out of the 
plane and lose double-bond character, assisting in catalysis. Most of the hydrogen bonds 
between the substrates and the enzyme involve the backbone of the substrates.(38) 
Therefore the substrate specificity arises mainly from nonpolar interactions between the 












Figure 1.5: Flexible regions of HIV Protease. 
Violet: Flap. Gold: Cantilever. Pink: Fulcrum. Green: Fireman’s grip. Catalytic aspartates 
are shown in ball and stick model. Redrawn from (32, 36).  
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1.1.6.3 HIVP substrate specificity 
HIVP cleaves the Gag-Pol polyprotein at least at eight different locations; Table 1.1 
presents the P4 to P3’ amino acid sequences flanking these cleavage sites. The substrates 
can be grouped into two types, based on the amino acids immediately flanking the 
scissile bond: “–aromatic * Pro-“ , and “–hydrophobic * hydrophobic-“. The interactions 
of these substrates with HIVP are typically analyzed in terms of seven subsites, S4-S3', 
within the binding site (40).  For example, the branched amino acids (Val or Ile) are 
preferred at the P2 position in substrates of the –hydrophobic * hydrophobic- type, while 
Asn is prefered at this position in the –aromatic * Pro- types.  Interestingly, although 
though there is no S5 subsite, Lys at P5  position significantly enhances the catalysis of 
substrates with a -hydrophobic * hydrophobic cleavage site, and also can significantly 
affect catalysis for the -aromatic*hydrophobic- junction (40). Thus, substrate residues at 
long distances from the scissile peptide bond contribute to HIVP specificity.  However, 
although it is conceivable that entire flanking domains of the Gag-Pol polyprotine might 
also be involved in binding to HIVP and to substrate specificity, such interactions to not 






















Ser Gln Asn Tyr * Pro Ile Val 
Ser Phe Asn Phe * Pro Gln Ile 
Aro*Pro 
 
Thr Leu Asn Phe * Pro Ile Ser 
         
Ala Arg Val Leu * Ala Glu Ala 
Ala Thr Ile Met * Met Gln Arg 
Pro Gly Asn Phe * Leu Gln Ser 




Arg Lys Val Leu * Phe Leu Asp 
 
Table 1.1: Substrate sequences from P4 to P3’.   
The cleavage site is denoted by *. Reproduced from Griffiths etal (41). 
 
1.1.6.4 Mechanism of catalysis 
The aspartic proteases catalyze hydrolysis of their substrates through a general acid-base 
mechanism. This proteolysis takes place in four steps (Figure 1.6). The peptide carbonyl 
is hydrated by an active-site water in the first step of catalysis (Figure 1.6a). There is also 
translocation of a proton between the active site aspartates. In the second step, the scissile 
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peptide bond adapts a gauche conformation (Figure 1.6b).  The flexibility of the hydrated 
bond leads to this conformational transition. The gauche conformation facilitates proton 
transfer in the third step (Figure 1.6c). This proton exchange involves simultaneous 
proton transfers from one hydroxyl group of active site water to the charged aspartate and 
from the second aspartate to the nitrogen lone pair of the hydrated peptide bond. Rotation 
of the proton donor aspartate around the Cβ–Cγ bond is required for this proton 
exchange. The final step involves the breakage of C–N peptide bond and regeneration of 















Figure 1.6: A model for HIV protease catalysis.  
(a) Hydration of the scissile amide bond. (b) Conformational transition. (c) Simultaneous 







1.1.7 HIV protease inhibitors 
HIV protease inhibitors are competitive inhibitors, in which the scissile P1-P1’ amide 
bond is replaced by a non-hydrolysable isostere such as a reduced amide,  
hydroxyethylene, hydroxyethylamine, azapeptide, etc (Figure 1.7) (43). Crystal structures 
of HIV protease-inhibitor complexes show that the enzyme structure is well preserved. 
This implies that the interaction pattern of inhibitors with the main chain of the protein 
remains the same, in spite of their differences in chemistry and structure. On 
superimposition, the functional elements were found to have a very good overall 
alignment. Most of the substrate-based inhibitors bind to the enzyme in an extended 
conformation(31).  Inhibitors with a hydroxyl group at the non scissile junction position it 
between the catalytic aspartates, within hydrogen-bonding distance to at least one 
carboxylate oxygen of each aspartate (Figures 1.8a and 1.8c). Interaction of inhibitors 
with a buried water molecule, that bridges their P2 and P1’ carbonyl groups and Ile50 and 
Ile50’ NH groups of the flaps, is one more common feature (Figures 1.8a and 1.8b). This 
water is completely separated from the bulk solvent. Most inhibitors have hydrophobic 












































Figure 1.7: Examples of non-hydrolysable isosteres of the peptide bond.  















Figure 1.8: Superimposed HIV protease-clinical inhibitor complexes. 
Crystal structures of Amprenavir, Indinavir, Saquinavir, Ritonavir and Nelfinavir in 
complex with HIV protease were superimposed to show the consensus hydrogen bonding 
interaction with flap water (a) and with catalytic aspartates (b). HIV protease is shown in 
ribbon model; the inhibitors, flap water and residues Asp25, Asp25’, Ile50 and Ile50’ are 
shown in licorice model.  
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Inhibitor-binding induces substantial changes in enzyme conformation. There is an 
approximate rotation of about 2 Å around the hinge region in the β-sheet interface. This 
rotation is accompanied by a large ~7 Å  motion of the flap regions, which leads to flap 
closure and tightens the active site (31). This tight conformation of the active site 
excludes bulk water, providing the dehydrated environment needed for catalysis or for 
inhibitor binding (45). Upon binding, clinical inhibitors such as Indinavir, nelfinavir, 
saquinavir and ritonavir bury a large amount of largely hydrophobic surface area. Hence, 
the main driving force for their binding is, arguably, provided by the hydrophobic effect 
(45). 
1.1.8 Clinical resistance 
Despite the initial success of anti-AIDS therapy, nowadays there is a worrisome 
emergence of viral strains that exhibit resistance (45). It is estimated that almost 14% of 
new infections in America and 10% in Europe are by treatment-resistant strains. Its high 
replication rate and error-prone reverse transcriptase makes this virus remarkably prone 
to mutation. As a consequence, the appearance of HIV variants with decreased 
susceptibility to clinical inhibitors can be viewed as inevitable (44).  
HIV protease, being a small enzyme and a homo-dimer, was initially thought of as an 
ideal target because of its limited mutational possibilities (46).  There was also a 
speculation that resistance mutations would not readily develop to HIV protease 
inhibitors, because the protease need to process nine different substrates (47). However, 
rapid emergence of strains resistant to HIV protease inhibitors completely changed the 
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initial perspective. There are at least 49 residues in HIV protease that undergo mutation, 
leading to resistance to one or more clinical inhibitors (45, 48). These mutations 
considerably reduce the affinity to inhibitors while retaining a viable enzymatic profile. 
HIV protease mutations can be classified as primary or secondary, based on their order of 
appearance in patients undergoing treatment. Mutations in the binding site are almost 
invariably primary mutations. They are generally conservative, preserving the charge and 
polarity of the active site but not the geometry (49). As few as two such mutations often 
suffice to reduce the binding affinity of inhibitors several hundred-fold (50). 
The effects of active site mutations on binding affinity are often relatively easy to 
interpret, as they are responsible for the loss of local van der Waals interactions or 
hydrogen bonds. The active site residues Asp30, Val32, Gly48, Ile50, Val82 and Ile84 
(Figure 1.9), are highly prone to mutation. As these sites directly interact with the 
inhibitors, most of them are signature mutations for specific inhibitors. For example, 
signature mutations for saquinavir are G48V and I84V; for indinavir and ritonavir are 
V82A/T/F/S and I84V; for nelfinavir are D30N and I84V; for amprenavir are I50V and 
I84V; and for lopinavir V82A/T/F/S (45).   
These active site mutations also affect the catalytic efficiency and maturation of Gag 
proteins, leading to impaired infectivity (51). Mutations at sites other than the active site 
have been found to compensate for this compromised catalytic activity (52). They also 
affects the binding of clinical inhibitors by causing a distortion in the geometry of 
binding site (53), and by stabilizing the open form of the protease (50). These effects of 
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non-active site mutations were proposed to have a greater effect on binding of rigid 
inhibitors rather than the binding of substrates (54). Hence viral strains that show 
phenotypic and genotypic resistance to multiple drugs have only one or two active site 
mutations and a constellation of non-active site mutations (53). The diminished catalytic 
activity was also compensated to a certain degree by the co-evolution of substrates with 


















Figure 1.9: Sites of signature mutations. 
Blue: Saquinavir. Red: Amprenavir. Orange: Nelfinavir. Green: Residues 82 and 84, that 
mutate with all clinical inhibitors. (a) Front view (b) Top view 
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1.1.9 Design strategies for mutation resistant HIV protease inhibitors 
The emergence of viral strains that are resistant to existing clinical HIV protease 
inhibitors has necessitated a search for novel inhibitors with broad specificity against 
treatment-resistant strains. The goal of our project is to design a combinatorial library of 
such inhibitors. Several plausible design strategies deserve consideration. This section 
gives a short list of such strategies and discusses their merits.  
The first strategy is to design inhibitors against multi-PI resistant variants. These variants 
carry various permutations and combinations of mutations in the protease. Hence it is not 
possible to include all the variants in screening, but it is possible to account for mutations 
at residues 10, 54, 71, 82 and 84, which occur frequently in multi-PI resistant strains. 
Therefore the strategy would be to design compounds that might not interact with these 
residues (58). Compounds having unique contacts with protease, such as TMC126, can 
be another category of novel mutation resistant inhibitors. The development of resistance 
to such an inhibitor will follow a different genetic pathway than the one due to the 
existing clinical protease inhibitors. Hence such inhibitors can be used in cocktail therapy 
with other protease inhibitors or for salvage therapy (59). 
Inhibitors can be designed to have flexibility in the regions that interact with residues that 
are prone to mutate (60, 61). This idea is based on the observation that highly flexible 
peptide substrates are more amenable to adapt to backbone rearrangements or subtle 
conformational changes induced by mutations in the protease. In contrast, more rigid 
inhibitors lose much of their affinity on minor changes in the geometry of the binding site 
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(62). This differential susceptibility to mutation leads to clinical resistance. Hence 
inhibitors that are flexible may evade resistance. It is difficult though not impossible to 
incorporate this criterion in massive in silico screening. 
The inhibitors that target open active site can be another set of candidate drugs. Most of 
the non active site mutations occur at domain interfaces, stabilizing protein in un-
liganded (open) state and thus increasing the off rate for existing inhibitors. Therefore 
drugs targeting open active site can selectively avoid the mutations that confer resistance 
in this manner (63).  
Design of compounds to have a volume consensus with substrates is another design 
strategy. It has been recently proposed that substrates are recognized by the protease by 
their volume rather than by their sequence or by their charge distribution. As these 
compounds would occupy the same volume as that of the substrates, any mutation that 
affects the binding of inhibitors would also affect the binding of substrates, and thereby 
affecting the viability of the virus. We selected this strategy for further scrutiny and 
evaluation in the design of a combinatorial library of mutation resistant HIV protease 
inhibitors. This strategy was also chosen based on its easy implementation and 
compatibility with our scoring algorithm (details are given in Chapter 2).  
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1.2 Combinatorial library design  
1.2.1 Combinatorial library and virtual screening 
Combinatorial library is a library of compounds that are related to one another, as they 
are built from same set of building blocks. Each compound in this library is a unique 
combination of these building blocks. There is a common structural core (combinatorial 
scaffold) between the members of this library, which has linking points for the building 
blocks (64). As there are huge number of available building blocks (synthetic reagents), it 
is not possible to synthesize and screen all possible combinations in the library for bio-
activity. Identification of subsets of compounds from this vast combinatorial library that 
have the best potential for the discovery of new leads is a daunting task. Computational 
methods (Virtual screening) are sought to pick such promising candidates for synthesis 
and in vitro screening.  
Based on the criteria used, virtual screening methods can be broadly classified into three 
classes. They are as follows: Cheminformatics-based, Ligand-based and Structure-based 
methods. The first class uses chemical descriptors or other chemical properties to select 
molecules based on drug-likeness, lead-likeness or diversity. The second class is used 
only when one or more active compounds were known. This method compares structural 
features of the screened compounds with the known actives. The last method is used 
when the structure of biological target and the key features of molecular recognition are 
known (65). Hence, selection of the virtual screening method depends on the level of 
available information.  The last two methods are more predictable than the first method 
(65).  
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Cheminformatics-based methods are used when there is no prior information on the target 
or the actives for this target. In this situation, it is desirable to screen combinatorial 
libraries for diverse chemistry with drug and lead-like characteristics and also without 
undesirable chemical properties such as toxicity(66). This virtual screening method thus 
involve evaluation of molecular similarity or diversity, which can be assessed by 
comparing molecular features expressed in binary fingerprints (67). These fingerprints 
carry information on molecular features such as presence or absence of structural 
fragments, aromatic character, flexibility, and hydrogen-bonding capacity of molecules. 
There are a variety of metrics, that are available to compare the fingerprints (68). 
Ligand-based methods are based on a pharmacophore model, which correlates molecular 
architectures with bio-activity. In this method compounds are screened for isofunctional 
molecular architecture that mimics the pharmacophore pattern in bio-active molecules. 
This method is especially useful, when there is limited or no structural information on the 
target. There are several software programs (HARPick (69), MoSELECT (70), TOPAS 
(71)) that use this method in the design of combinatorial libraries (72). 
When the structure of a target protein is known, structure based screening methods are 
widely chosen because of their potential to discover diverse chemistry. They are also 
preferred for the structural insights, which can guide the design and optimization of lead 
compounds. In the structure based methods, suitable combinations of building blocks are 
suggested based on their predicted binding affinity for a given receptor. These methods 
can be broadly classified as de novo and scaffold based. In the de novo based method, 
optimal building blocks (chemical fragments) that interact favorably with sub sites in the 
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binding cavity of a target protein are linked sequentially to build combinatorial 
compounds (73). Examples of such de novo based design algorithms include 
CombiSMoG (74),TOPAS (71), MCDNLG (73),  LUDI (75). The disadvantage of these 
methods is that the choice of an optimal fragment for an earlier link in the growth phase 
may not be optimal further down the growth chain. Certain programs such as 
CONCERTS (76) circumvent this problem by allowing the links to break and reform 
during the growth phase.  
Scaffold based design method involves linking building blocks (substituents) to an 
anchoring fragment (combinatorial scaffold) through the linking points (substituent 
positions). The combinatorial scaffold may be the one that provides the key interactions 
with target protein or a starting fragment in the synthetic route or the fragment to which 
other fragments are linked. Examples of this method include CombiDock (77) and 
PRO_SELECT (78).  
Structure-based virtual screening methods predict the binding affinity of a given 
compound by docking them in the target active site and scoring the docked poses. 
Examples for the programs that are widely used for this purpose are DOCK(79), 
GOLD(80), AutoDock(81), FlexX(82), PRO_LEADS(83) and GLIDE(84). The 
following two sections give a brief introduction on the docking and scoring functions and 
on VDock(85, 86), one such function that we use in our combinatorial library design. 
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1.2.2 Docking and scoring 
Docking is a computational method that uses the structure of a targeted protein to aid in 
the discovery of new ligands. It involves generating putative binding poses of candidate 
ligand in the target’s active site and scoring these poses for their predicted binding 
affinity (65). Kuntz and coworkers pioneered this approach with their geometric method 
of fitting compounds into the binding site; this method was later named DOCK (87). 
Since then, numerous other approaches have been developed that vary in their scoring 
functions, their approaches to treating the flexibility of ligand and protein, and their 
algorithms for discovering low energy conformations of the ligand- protein complex.  
There are three categories of scoring function: force-field based, empirical and 
knowledge-based. The force-field based methods compute the binding energy in terms of 
van der Waals and Coulombic potentials from a molecular mechanics force field. 
Docking programs that use this approach include AutoDock (81), DOCK (79) and 
VDock (85, 86). An empirical scoring function uses fitted hydrogen bonding, ionic and 
hydrophobic energy terms, which are calibrated based upon complexes of known affinity. 
The docking programs FlexX (82), AutoDock (87), ChemScore (88) and LUDI (89) use 
this approach. Knowledge-based potentials, such as BLEEP (90), PLP (91), PMFScore 
(92) and DrugScore (93),  are based on observed atom-atom distributions among a large 
set of protein-ligand structures. (65). 
Different docking proteins account for the flexibility of ligands and proteins in greater or 
lesser detail. One approach to handling ligand flexibility is to precompute a set of ligand 
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conformations, and then dock them all as rigid components into the binding site.  This 
approach is employed by a number of methods, including EUDOC (94), FLOG (95) and 
LigandFit (96).  Another approach, used in programs such as FlexX (82) and DOCK (79), 
considers the ligand as a series of rigid molecular fragments. After positioning a key 
anchoring fragment in the active site, the other fragments are added to it in a step-wise 
fashion in such a way as to optimally fit the ligand into the binding site.  Finally, a 
number of other programs use global optimization methods, such as Metropolis Monte 
Carlo (MC) (97, 98), Tabu search (83) and Genetic Algorithm (GA) (99), to seek the 
lowest-energy conformation of a flexible ligand in the binding site. Examples of this 
approach include GOLD (80), AutoDock (81), VDock (85, 86), GLIDE (84) and 
PRO_LEADS (65).   
Docking methods are typically evaluated based upon their ability to reproduce the 
experimentally observed conformations of bound ligands.  In many cases, the predicted 
conformations lie within a root-mean-square deviation (RMSD) of 2.0 Å  On the other 
hand, the computed structure of lowest RMSD is not always the one with the most 
favorable docking score, due to errors in the the scoring function (65).  Docking 
programs are also tested for their ability to score the known ligands of a targeted protein 
higher than a set of background (“decoy”) compounds that are not thought to bind the 
target.  When a mixture of known ligands and decoys are scored, most programs provide 
substantial enrichment of known ligands among the top-ranked compounds (74, 100, 
101).  However, it is important to recognize that performance on such tests depends upon 
the details of the comparisons.  For example, it is typically easier to assign high scores to 
 34
ligands that bind the target tightly than to lower-affinity ligands.  Also, the known ligands 
are harder to differentiate from the decoy compounds when the decoys are more drug-like 
(65).  
1.2.3 VDock 
VDock is a force-field based docking algorithm developed in our lab. This program uses 
a rigid protein model. In the calculation of protein-ligand interaction energy, it is 
computationally expensive to include all non bonded interactions, as they are numerous. 
The fact that the protein atoms are fixed in the calculations, enables us to pre-compute the 
potentials (electrostatic potentials, and Lennard-Jones potentials) generated by all protein 
atoms in advance, and storing these potentials on a grid.  Protein-ligand interaction 
energy can then be computed from the interaction between ligand atoms and grid points. 
These grids (electrostatic, steric and dispersive grids) with lattice spacings of 0.2 A° are 
generated using CHARMM 22 force field parameters and an implicit solvent model with 
a distance dependent dielectric constant, ε = 4r , where r is the distance between the grid 
point and the receptor atom (88).  The grid dimensions are chosen to encompass all 
regions that mobile ligand atoms might enter.  
VDock models the ligand as flexible by explicitly considering all torsional degrees of 
freedom along with translational and rotational mobility. As stated earlier, it is not 
possible to thoroughly investigate the huge conformational space that results from the 
inclusion of all degrees of freedom in the generation of conformers. Hence, VDock uses 
mining minima optimizer to find low energy conformations from this huge search space. 
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This mining minima assumes a hierarchical binding energy landscape, where low energy 
structures are close to each other and clearly separated from high energy structures. This 
optimizer combines principles from global-under estimator method (89) and GA (85). 
During the search using a pseudo global-under estimator, a large number of candidate 
ligand conformations are generated randomly within the sampling range, which is 
gradually narrowed around the current low-energy conformer. When a new low energy 
conformation is generated, the center of the sampling range is moved to this new 
conformer. Once the sampling range is narrowed to zero, a local energy minimum is 
found. This local minimum is kept in memory for use in later cycles of sampling by GA. 
A detailed description of GA is given in section 1.2.4.  
Initial pseudo global-under estimator search results in multiple local minima, whose 
number is user defined. In GA, these local minima are recombined with random 
conformation through cross over. This recombination of partial solutions, resulting from 
the earlier pseudo global-under estimator search, accelerates the discovery of global 
optimum (85). 
The energy of protein-ligand conformation generated during the search is computed from 
the sum of vanderWaals and coulombic interactions, using three pre-computed grids of 
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th grid point, respectively. 
126 / rA σε≡ iiii and
63 / rB σε≡ iiii . iε , iσ are the Lennard-Jones parameters and r is the 
distance between the atom and the grid point. The interaction energy of a compound is 
given by the energy of the lowest energy conformation generated in docking runs. These 
interaction energies serve as fitness for the tested compounds (85). 
VDock had been shown to have comparable performance in the reproduction of 
crystallographic binding pose, with popular docking programs such as PRO_LEADS, 
AutoDock, FlexX, MCDOCK and GOLD (85). The second criterion for validating a 
scoring function is the enrichment ability. It is the ability to select known actives against 
a background of decoy compounds for a target protein. It is tested by docking both active 
and decoy compounds into the corresponding target protein. The entire set of compounds 
is then ranked as per their interaction energy. The concentration of known binders in the 
top of the ranked list determines the enrichment ability of the docking program. If the 
scoring had been ideal, all the actives will be concentrated in the top of the ranked list, 
where as if it had been a random selection, the actives will be distributed uniformly 
through out the ranked list. 
Enrichment ability of VDock is shown in Figure 1.10. The reported actives and NCI 
diversity set were used as known actives and decoys, respectively for this experiment. 
The random selection of compounds would yield an enrichment plot along the diagonal. 
i.e, 10% of the actives can be recovered from top 10% of the ranked database. The 
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greater the shift of the line towards left, greater is the enrichment. VDock is shown to 
have remarkable enrichment ability with our target protein, HIV protease. This justifies 
the use of VDock in our combinatorial library design. 
Even though computational evaluation of a candidate compound by VDock can be fast 
(seconds to a few minutes of computer time per compound), the computational demands 
can become problematic for the exhaustive screening of virtual combinatorial libraries. 
Optimization methods such as GA and simulated annealing methods are therefore, used 
in selecting an experimentally tractable sub library from among this astronomical number 













Figure 1.10: Enrichment graph for VDock with several target proteins. 
 Black: Factor Xa. Purple: Cyclin Dependent Kinase2. Green: Androgen receptor. Blue: 
Peroxisome Proliferator Activated Receptor.  Orange: Neuraminidase. Red: HIV 
Protease. (Courtesy: Dr Visvaldas Kairys) 
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1.2.4 Genetic algorithm 
Optimization algorithms are widely used in the design of combinatorial libraries that use 
both ligand-based (90, 91) and structure-based methods for the evaluation of compounds. 
One such method is genetic algorithm (GA), a stochastic method that mimics Darwinian 
evolution. In the combinatorial problem, each entity is a unique combination of a set of 
parameters that defines the position of this entity in the search space. Merit of each entity 
is a prospective solution to the combinatorial problem. The GA represents each 
individual entity as a “Chromosome”, a linear series of genes. Each parameter is 
represented by a gene, which has a set of values that are represented by alleles. A random 
population of chromosomes is created in the first generation of the program, which are 
then scored for their fitness.  A new population of chromosomes is constructed from the 
few selected, first generation chromosomes through cross over, mutation and 
reproduction. The chromosome selection for the propagation is biased to favor those with 
better fitness score. In the cross over operation, selected parent chromosomes swap a part 
of their chromosome resulting in two new chromosomes with different combination of 
alleles. Mutation results in change of one or more alleles in the parent chromosome. 
Reproduction is a mere replication of the parent chromosome. The new population is 
scored in turn and the iteration continues. Typically the average and maximum fitness 
score of the population increases with each generation until they converge to some 
maximum value. GA is especially useful in the search of large combinatorial search 
space, knowledge of whose terrain is very limited (90). 
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In the combinatorial library design problem, each chromosome represents a compound in 
the virtual combinatorial library, each gene corresponding to one substitution site, each 
allele of a gene corresponding to a candidate substituent (building block) at the site and 
the fitness of a chromosome corresponding to the interaction energy score predicted by 
VDock. The implementation of the genetic algorithm in our combinatorial library design 
is explained in detail under section 3.2.1 
1.3 Overview of the thesis  
This thesis is organized as follows. Chapter 2 introduces the substrate envelope 
hypothesis, describes the calculation of the fit of a candidate inhibitor to the substrate 
envelope with a grid based method, and evaluates the correlation of this score with 
susceptibility to resistant mutations. Chapter 3 compares a combinatorial library design 
strategy based on a simple additivity scheme that assumes independence among 
substitution sites, with a strategy based upon a genetic algorithm. Chapter 4 describes the 
application of the Additivity design strategy in the discovery of mutation-resistant HIV 
protease inhibitors. This process is found to yield two tightly binding compounds with 
desirable resistance profiles. Chapter 5 provides a general discussion and a prospectus for 
future research work. The major conclusions of the full project are summarized in chapter 
6. 
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Chapter 2. The Substrate Envelope Hypothesis  
2.1 Introduction 
Inhibitors of Human Immunodeficiency Virus (HIV) protease revolutionized the 
treatment of patients infected with HIV in the mid-1990s, and remain a mainstay of 
therapy today (25, 92, 93). However, recent years have seen the emergence of HIV 
strains that are resistant to protease inhibitors (48, 94).  The appearance of resistance is 
traceable to the selective pressure of therapy, combined with the high replication rate of 
HIV and the low fidelity with which HIV replicates its genetic information. Overcoming 
the evolutionary power of this system and maintaining an active armamentarium against 
HIV may prove to be a substantial challenge.  On the other hand, this challenge is 
circumscribed by the fact that a viable resistance mutant of HIV protease must still bind 
and hydrolyze the various cleavage sites of the virus’s Gag-Pol gene product at an 
adequate rate to allow viral replication.  Accordingly, it has been argued that an inhibitor 
which forms “substrate-like” interactions with the protease should tend to evade viral 
resistance, because a mutation that weakens inhibitor-binding should simultaneously 
weaken substrate-binding, and hence damage the activity of the enzyme.  
Recent crystallographic studies of complexes of HIV protease with its substrates provide 
a basis for pursuing this design concept.  The substrates adopt a rather uniform shape 
when bound, despite the differences among their amino acid sequences, and the border of 
the consensus volume they occupy has been termed the “substrate envelope” (95). 
Intriguingly, the consensus volume occupied by a number of bound inhibitors differs 
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significantly from the consensus substrate volume, and key resistance mutations appear to 
cluster near locations where inhibitors protrude outside the substrate envelope (96).  
These observations have led to the hypotheses that the protease recognizes its various 
substrates largely on the basis of their shape, and that inhibitors that fit within the 
substrate envelope may be less susceptible to mutational resistance (96). Indeed, it has 
been argued that the fit of inhibitor TMC-114 to the substrate envelope helps explain its 
ability to retain affinity for clinically relevant protease mutants (97, 98).   
These considerations suggest that the substrate envelope hypothesis may be useful as a 
basis for the design of new inhibitors that will tend to counteract the emergence of 
resistance mutants. The present study addresses this issue by devising a quantitative 
indicator of the degree to which a candidate ligand falls outside the substrate envelope, 
and then determining whether this indicator correlates with the inhibitor’s sensitivity to 
clinically relevant resistant mutations. The resistance analysis is based upon new 
calorimetric data for the association of various inhibitors with wild-type and mutant 
proteases, supplemented by additional calorimetric data from the literature. 
2.2 Materials and methods 
This section describes a method of quantifying the volume of a bound inhibitor falling 
outside the envelope, then details the measurement of affinities by isothermal titration 
calorimetry (ITC) for a group of inhibitors and proteases, and summarizes additional 
binding data drawn from prior publications. Finally, a novel measure of the “clinical 
relevance” of the mutant proteases is described.  
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2.2.1 Computational methods 
2.2.1.1 Evaluation of the fit of an inhibitor to the substrate envelope 
A 3D grid of substrate density in the binding site was generated as follows. The 
Superimpose module of QUANTA(99) was used to superimpose six crystal structures of 
HIV protease having bound substrate peptides (1F7A, 1KJ4, 1KJ7, 1KJF, 1KJG, 1KJH 
(37)) on a crystal structure of HIV protease with indinavir (1HSG(100)), based upon the 
coordinates of backbone atoms (Figure 2.1).  The chemical C2 rotational symmetry of the 
receptor structure was accounted for by carrying out the symmetry operation and 
superimposing the six resulting structures on the original six by the same method, for a 
total of 12 overlaid substrates. Next, a cubic three-dimensional grid with side-length 10 Å 
and grid spacing 0.2 Å was centered on the active site, and an initial value of 0 was 
assigned to each grid point.  Then a value g(i,j,k) was incremented by 1 for every 
substrate structure that contains the grid point (i,j,k), where a grid point was considered to 
be contained by a substrate if it lies within the CHARMm (101) van der Waals radius of 
any non-hydrogen atom of the substrate. Because there are 12 overlaid substrates, the 
















The fit of an inhibitor to the substrate envelope is computed as follows.  A crystal 
structure of HIV protease with the bound inhibitor is aligned with the substrate-bound 
structures, as described above. Then the effective volume of the inhibitor outside the 
substrate envelope, Vout, is computed by summing the values of the grid points gijk that lie 
within the van der Waals volume of the inhibitor, normalizing the sum by 12, and 
converting to a volume by multiplying by the 0.008 Å3 volume of a grid box: 
, ,
(12 )





Here “inside” implies that the sum runs only over grid points ijk that lie within the van 
der Waals volume of the inhibitor. As a control, the effective volume of the inhibitor that 








The total volume of an inhibitor, Vtot, is computed by adding these two quantities.  The 
molecular weight and the number of non-hydrogen atoms were also included as 
alternative measures of molecular size.  
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The following crystal structures of HIV protease with bound inhibitors were drawn from 
the Protein Data Bank (33): 1HPV (102) (amprenavir; APV), 1HXB (103) (saquinavir; 
SQV), 1HSG (100) (indinavir; IDV), 1OHR (100) (nelfinavir; NFV) and 1HXW(21) 
(ritonavir; RTV). These structures were used to compute the values of Vout, Vin and Vtot 
(see above) of the respective inhibitors.  
2.2.2 Binding data 
The degree, to which an inhibitor's affinity declines when a mutant protease is substituted 
for wild-type, is quantified as , where K  and K represent 
the inhibitor’s dissociation constants for the mutant and wild-types, respectively. 
Dissociation constants from isothermal titration calorimetry (section 2.2.2.1) were 
obtained from our collaborators lab and from the literature (subsequent subsection). In 
each case, the ratio of mutant to wild-type is drawn from a single study to minimize noise 
due to experimental variations.  
)/log( typewildmut KK − mut wild type−dd d d
2.2.2.1 Literature Data 
The new calorimetric data from the collaborators lab were supplemented with data drawn 
from the literature, including results for proteases with mutations only in the active site, 
only outside the active site, and both in and out of the active site.  One study examines 
the consequences of mutants with a single mutation in the active site (I84V), multiple 
mutations outside the active site,  (NAM10: L10I/M36I/S37D/M46I/R57K/L63P/A71V 
/G73/L90M/I93L) and their combination (ANAM11: L10I/M36I/S37D/M46I/R57K/ 
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L63P/A71V/G73S/L90M/I93/I84V), upon resistance to a number of clinical inhibitors 
(53).  A second study examines cooperativity among mutations V82A/I84V in the active 
site, M46I/I54V in the active site flaps, and L10I/L90M in the dimerization region away 
from the active site, as well as the combinations, HM (L10I/M46I/I54V/V82A/ 
I84V/L90M) and QM (V82A/I84V/M46I/I54V) (104). A third study examines the active 
site mutation V82F/I84V against the background of viral strains A, B and C (105). 
2.2.3 Clinical relevance of mutations 
Treatment of a patient with HIV protease inhibitors selects for mutations that disrupt 
inhibitor binding while preserving enzyme function.  If the substrate envelope hypothesis 
is valid, then inhibitors that fit the substrate envelope well should tend to retain affinity in 
the face of such clinically relevant mutations, but not necessarily to artificial mutations, 
which might disrupt the normal interactions of the enzyme with its substrates. The 
clinical relevance of the mutations studied here is assessed based upon their tendency to 
occur in patients treated with protease inhibitors, and in the absence of concurrent 
mutations known to be major resistance mutations. Thus, a combination of mutations is 
considered clinically relevant if clinical data suggest that it alone suffices to generate 
clinical resistance.  Clinical data drawn from the HIV Drug Resistance Database (106) 










where Ni,only is the number of isolates with mutation set i and no other major mutations, as 
defined at the Drug Resistance Database (http://hivdb.stanford.edu/cgi-bin/PRMut.cgi); 
and Ni,all is the total number of isolates with mutation set i.  That is, Ni,all includes isolates 
with other major mutations.   
2.3 Results 
2.3.1 Fit of inhibitors to substrate density 
Isodensity contours of the substrate density grid (Figure 2.2) show a rather smooth 
gradation of density, rather than a sharp drop from the maximal value of 12 to the 
minimal value of 0.  The absence of an unambiguous substrate envelope motivates the 
present use of a smoothly varying measure of the volume of an inhibitor lying outside the 
substrate region (Equation 2.1), rather than a sharp cutoff.  The consensus volume that is 
covered by all 12 substrate poses is rather constricted (red in Figure 2.2).  It seems 
unlikely that an inhibitor could achieve high affinity without reaching outside this region.  
In fact, the inhibitors studied here all extend to some degree outside the level 8 contour, 
APV the least and RTV the most (Figure 2.3).  This observation is quantified in the first 
row of Table 2.1, which lists the computed values of Vout (Equation 2.1) which range over 
a factor of 2.  The computed volumes within the substrate envelope are more uniform, 
varying by only about 20%.  Table 2.1 includes other measures of molecular size as well. 
2.3.2 Binding affinities to wild-type protease and mutants 
Table 2.2 lists the sensitivities ( of inhibitors to mutations MDR5, 




The affinity losses vary from 0.3 to nearly 4 logs. APV tends to lose least affinity to these 
mutations, while RTV tends to lose the most.   
 50
 










Figure 2.2: Isosurface contours of the substrate density. 
Backbone trace of HIV-1 protease is also shown. Red: density 12. Green: density 8. Blue: 











 b) a) 
Figure 2.3: Two views of level 8 isodensity contours of the substrate density overlaid 
with crystal structures of clinical inhibitors. 
The contours are shown in green color. Red: Amprenavir (APV). Cyan: Indinavir (IDV). 
White: Saquinavir (SQV). Purple: Nelfinavir (NFV) and Yellow: Ritonavir (RTV).  The 
active site residues I82, V84, and G48 are shown with red spheres. The hydroxyl groups 




 APV IDV SQV NFV RTV 
Vout 128 180 213 166 256 
Vin  267 315 319 288 308 
Vtot 395 495 531 454 564 
Non-hydrogen atoms 35 45 49 44 50 
Molecular weight 
(Da)  506 614 671 664 721 
Table 2.1: Computed volumes (Å3) of inhibitors, with other measures of molecular 
size.  
Vout: volume outside the substrate envelope. Vin: volume within the substrate envelope. 






MUTATION SETS APV IDV SQV NFV RTV 
MDR5 (L10I/G48V/I54V/L63P/V82A) 0.52 1.88 2.55 1.94  
MDR3 (L63P/V82T/I84V) 0.77 1.69 2.13 1.69  
NAM10  
(L10I/M36I/S37D/M46I/R57K/L63P/A71V/G73S/L90M/I93L)  2.80 3.06 3.10 3.95 
ANAM11 
(L10I/M36I/S37D/M46I/R57K/L63P/A71V/G73S/L90M/I93/I84V)  2.98 3.29 3.13 4.56 
I84V  0.57 0.60 0.54 1.73 
V82F/I84V 
(Strain A)  1.78 1.34 1.34 2.58 
V82F/I84V 
(Strain B)  1.83 1.32 1.30 2.57 
V82F/I84V 
(Strain C)  1.85 1.32 1.30 2.58 
L10I/L90M 0.60 0.48 0.78 0.47 0.58 
M46I/I54V 0.31 0.16 0.85 0.28 0.65 
V82A/I84V 0.74 1.20 0.90 0.28 1.31 
QM (V82A/I84V/M46I/I54V) 1.19 1.46 2.19 1.27 2.15 
HM (L10I/M46I/I54V/V82A/I84V/L90M) 1.93 2.30 3.29 2.33 3.18 
Table 2.2: Resistance values of five inhibitors and 13 HIV protease mutants. 






d values for MDR3 and MDR5 were kindly provided 




2.3.3 Clinical relevance of protease mutants 
Clinical relevance of the studied mutations is given in Table 2.3. The mutants analyzed 
here appear to span a range of clinical relevance, as computed with Equation 2.3.  The 
mutation sets of MDR5, QM and HM are found in a significant fraction (19-44%) of 
clinical isolates having no other major mutations; mutation sets MDR3, I84V, 
L10I/L90M and V82A/I84V appear in 2-5% of isolates with no other major mutations; 
and V82F/I84V, M46I/I54V appear in <1% of isolates without other major mutations. 
Mutation sets NAM10 and ANAM11 were not observed in any of the clinical isolates 
studied in Stanford database (48).  
2.3.4 Correlation of Vout with sensitivity to clinically relevant mutations 
Figure 2.4 examines the correlation of Vout, Vin, Vtot, number of nonhydrogen atoms, and 
molecular weight, with the loss of affinity of the various inhibitors on going from wild-
type to the most clinically relevant protease mutants, MDR5, QM and HM. The data are 
drawn from Tables 2.1 and 2.2.  The corresponding correlation coefficients for these 
mutants, and for the other, less clinically relevant mutants, are provided in Table 2.4.  
The volume of an inhibitor that lies outside the substrate envelope, Vout, correlates 
strongly with its susceptibility to the four most clinically relevant mutations, with 
correlation coefficients 0.94 – 0.97.  Similar correlations are observed for many of the 
other mutants, but not all: the correlation coefficients range from 0.28 to 0.97.  
Interestingly, the other measures of molecular size show rather similar patterns.  The 
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correlations tend to be weakest for Vin, if only because this quantity has a rather small 
range of values.   
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MUTATION SETS NI,ONLY NI,ALL
CLINICAL 
RELEVANCE 
MDR5 (L10I/G48V/I54V/L63P/V82A) 14 75 18.67 








0 0 0 
I84V  20 807 2.48 
V82F/I84V (Strain A) 0 4 0.00 
V82F/I84V (Strain B) 0 4 0.00 
V82F/I84V (Strain C) 0 4 0.00 
L10I/L90M  62 1264 4.91 
M46I/I54V 1 390 0.26 
V82A/I84V  4 166 2.41 
QM (V82A/I84V/M46I/I54V) 7 28 25.00 
HM 
(L10I/M46I/I54V/V82A/I84V/L90M) 4 9 44.4 
Table 2.3: Clinical relevance of HIV protease mutants. 
Ni,only: number of clinical isolates having the listed mutations and no other major 
mutations. Ni,all: total number of clinical isolates with the listed mutations. Clinical 
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Figure 2.4: Correlation plots for the computed volume and other measures of size 
with the resistance. 
Resistance is computed as the log loss in affinity on going from wild-type to mutant, for 
the three most clinically relevant mutants. Volume measures are given in cubic 










(L10I/G48V/I54V/L63P/V82A) 0.96 0.88 0.94 0.99 0.96 
MDR3  








0.94 0.17 0.84 0.79 0.83 
I84V  0.89 0.10 0.77 0.71 0.81 
V82F/I84V   
(Strain A) 0.77 0.17 0.71 0.55 0.56 
V82F/I84V  
(Strain B) 0.75 0.20 0.69 0.52 0.50 
V82F/I84V  
(Strain C) 0.75 0.20 0.69 0.52 0.50 
L10I/L90M  0.28 0.28 0.30 0.04 0.10 
M46I/I54V 0.68 0.46 0.65 0.60 0.53 
V82A/I84V  0.62 0.57 0.63 0.44 0.22 
QM  
(V82A/I84V/M46I/I54V) 0.91 0.75 0.91 0.84 0.73 
HM  
(L10I/M46I/I54V/V82A/I84V/L90M) 0.91 0.75 0.91 0.89 0.82 
Table 2.4: Correlation coefficients of resistance with inhibitor properties.   




The present results support the hypothesis that HIV protease inhibitors that conform 
better to the substrate envelope tend to be less susceptible to resistance mutations.  The 
presumptive explanation is that a viable mutant must allow the protease to interact 
correctly with its substrates and so it will also tend to retain affinity for a substrate-like 
inhibitor. The present data do not definitively establish this mechanism, especially 
because nonspecific measures of inhibitor size, such as molecular weight, also are found 
to correlate with sensitivity to mutation. On the other hand, these additional correlations 
do not disprove the presumed mechanism; they may merely reflect the correlation of 
molecular weight, say, with Vout.  Teasing apart the various correlations will require 
further studies.  The ultimate aim of the present study, however, is to facilitate the design 
of new inhibitors that will resist mutation.  It will therefore be of particular interest to 
observe the consequences of using the fit of candidate inhibitors to the substrate envelope 
as a figure of merit in computer-aided ligand-design.  
The present analysis generalizes the notion of the substrate envelope to that of a substrate 
density, which falls rather gradually to zero from its maximum at the core of the substrate 
binding region.  This approach provides more detailed information about the disposition 
of substrates in the binding site, as highlighted in Figure 2.2a, and avoids the need to set 
an arbitary level of substrate density at which to position a sharp substrate envelope.  The 
substrate density is encoded on a 3D grid, allowing rapid calculation of the fit of a 
docked ligand to the substrate density.  Analogous maps of ligand density, or of the 
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density of a flexible receptor, could be useful in describing and modeling other molecular 
systems as well.  
The present study evaluates the clinical relevance of protease mutations based upon the 
sequences of clinical isolates.  For example, L10I/L90M occurs rarely in the absence of 
other major mutations (clinical relevance 4.9, Table 2.3), presumably because these two 
mutations alone confer less than one log of resistance to the clinical inhibitors that were 
studied here (Table 2.2).  An alternative approach to assessing clinical relevance might 
have been to rely on in vitro vitality scores of the mutant proteases (45), which account 
for the enzymatic activity of the mutant against substrate. However, these data are 
unavailable for many mutants.  In addition, the vitality may vary across substrates, 
whereas the clinical relevance score used here implicitly accounts for multiple substrates. 
This distinction may help explain why V82A/I84V (clinical relevance 2.4, Table 2.3) 
appears more frequently than V82F/I84V (clinical relevance 0, Table 2.3) in clinical 
isolates lacking other major mutations, despite the fact that the clinical inhibitors retain 
activity better against V82A/I84V than against V82F/I84V (Table 2.2), and both mutants 
affect the catalysis of a model substrate similarly (105).  It is also worth noting that, 
although all the clinical inhibitors position the hydroxyethylene hydroxyl group outside 
the substrate envelope (Figure 2.3), this deviation should not provide a basis for 
resistance mutations because the hydroxyl contacts residues D25/D25', which are 
essential for catalysis and therefore are clinically irrelevant. 
In summary, the failure of an HIV protease inhibitor to fit within the substrate envelope 
does appear to correlate with its susceptibility to mutational resistance. This is a low-
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resolution approach so exceptions will undoubtedly be found, and more rigorous 
approaches to identifying robust inhibitors are still needed.  However, until such methods 
are available, the trend observed here suggests that designing ligands not only for tight-
binding but also for fit to the substrate envelope could help accelerate the discovery of 
robust inhibitors of HIV protease.  
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Chapter 3. Combinatorial Library Design 
3.1 Introduction 
The compounds in a typical combinatorial library are built around a common structural 
scaffold possessing multiple connection points where substituents can be added by 
reliable synthetic steps (107). This format allows the efficient synthesis of many 
candidate inhibitors of a target protein. However, the number of compounds 
encompassed by such a combinatorial scheme frequently exceeds what can actually be 
synthesized and tested. This situation can be addressed by making and testing smaller 
sub-libraries where the compounds are selected based upon their similarity to known 
ligands (70) and/or their fit to the targeted binding site (77, 78). The present study 
focuses on the structure-based method, using ligand-protein docking. This method is 
expected to possess the advantages of yielding candidate ligands of diverse chemistries 
and of providing physical insight into interactions between ligand and protein.  On the 
other hand, docking calculations tend to be more time-consuming than ligand-based 
methods, since one docking calculation typically requires seconds to minutes of CPU 
time. As a consequence, there is a particularly strong requirement for a library design 
algorithm that will make the best possible use of available computer resources.   
One approach to the problem of library design is to apply a global optimization method, 
such as a genetic algorithm (108, 109). Successful applications of genetic algorithms in 
the design of both ligand-based combinatorial libraries (110-112) and the prediction of 
binding affinity have been previously reported (108, 109). A combinatorial sub-library 
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designed via global optimization should perform significantly better than a randomly 
chosen sub-library.  However, it is not clear whether global optimization methods can 
perform as well at picking chemical substituents as they do in more typical applications 
where the objective function depends upon better-defined degrees of freedom. A specific 
concern in the present application is that there is no guarantee that the GA will test every 
possible substituent at each position and, if it does not, the best substituents may well be 
missed. 
Another approach to optimizing a combinatorial library using structure-based methods is 
to simplify the problem by assuming that the substituent sites can be optimized at least 
somewhat independently.  This can be done, for example, by constructing an initial 
compound with an arbitrary set of initial substituents, and then making new compounds 
in which each position is converted to all other possible substituents, while the other 
substituents are held fixed.  For a library with 4 substitution sites and 1000 candidate 
substituents at each site, this would yield almost 4000 compounds to be docked and 
scored, far fewer than the full virtual library of 10004=1012 compounds.  The substituents 
which yield the best scores can then be selected and used to build a manageable set of 
compounds to be tested individually by docking and scoring. The approximation of 
independence provides for a dramatic acceleration in library evaluation, but if it is 
inaccurate, the best compounds may be missed. We are not aware of any systematic 
evaluation of the suitability of this approximation. Even though the idea of additivity has 
been employed in PRO_SELECT (78) and CombiDock (77), a comprehensive evaluation 
has not been discussed to date. 
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The present study evaluates the accuracy of additivity in docking and scoring of 
combinatorial libraries, tests its applicability to the design of targeted combinatorial 
libraries, and compares its productivity with that of a genetic algorithm method of library 
design, in applications to two model systems, HIV protease and cathepsin.  For each 
system, three scenarios are considered: 1) design of sublibraries of a virtual library 
containing thousands of compounds with diverse substituents; 2) design of sublibraries of 
a virtual library containing thousands of compounds with substituents preselected to 
generate promising ligands; and 3) design of sublibraries of a virtual library containing 
millions of compounds with diverse substituents.  The smaller virtual libraries allow 
more detailed characterization of the design methods because every compound in this 
library can be docked and scored. The larger libraries are more representative of real-
world applications. 
3.2 Methods 
The methods section is organized as follows. The first three subsections describe the 
implementation of the design methods and their evaluation. The next two subsections 
describe the construction of combinatorial compounds, and the selection of substituent 
libraries for the studied test systems.  The last two subsections provide details on the 
preparation of target protein structures and on the docking and scoring methodologies. 
3.2.1 Genetic algorithm 
A genetic algorithm (GA) is a stochastic optimization method that mimics the evolution 
of a population of chromosomes through a series of generations, where each chromosome 
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represents a candidate solution for the optimization problem (108-112). For each 
generation, the objective function (fitness) is evaluated for each chromosome, and a new 
generation is formed by directly transferring a few top-scoring chromosomes (elites) 
from this generation to next one and by forming the rest of the population through 
processes mimicking crossing-over and single-site mutation.  This process is repeated for 
a selected number of generations or until some criterion of convergence has been met. In 
this work, each chromosome represents a compound, each gene corresponds to one 
substitution site, and each allele of a gene corresponds to a candidate substituent at the 
site (Figure 3.1). The fitness of a chromosome is evaluated by constructing the 
corresponding compound and docking it to the target protein (section 3.2.7).  
The GA used here is modified slightly for the sake of efficiency. The chief difference is 
that compounds in old generations are not discarded, but also are not brought forward 
into successive generations; i.e., no elite compounds are brought forward without 
modification. This change increases the number of compounds tested in one GA run. The 
second difference, based upon the first one, is that all chromosomes for the next 
generation are built by mutation and cross-over operations on parent chromosomes from 
not only the most recent generation but also from all prior generations. Parents are 
selected via the roulette-wheel method (113) where the probability of selecting a 
compound is proportional to its fitness rank. A predefined fraction of parents are used for 
cross-over operations; the rest are subjected to single-site random mutation.  The cycle of 
evaluation, selection and modification is repeated for a user-defined number of 
generations, and the output is the ranked set of all compounds tried.   
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The GA includes several important operational parameters: the number of generations, 
the number of chromosomes in each generation, and the percentage of parent 
chromosomes subjected to cross-over. The total number of compounds tried, and hence 
the total number of docking calculations, equals the generation size multiplied by the 
number of generations.  Except as otherwise noted, this total was kept as close as possible 
to the number of dockings used in the corresponding additivity-based calculations, so that 
the two methods could be compared on an equal footing.  Preliminary calculations 
showed that the performance of the GA depends strongly on choices made regarding 
population size versus number of generations, and on the crossover versus the mutation 
rates. In particular, the mean fitness of compounds was found to improve only slowly 
after 8 generations, so all GA calculations used ~8 generations, and the desired number of 
dockings was set by adjusting the population size.  The best overall results were obtained 
with a crossover rate of 25%, and this value was then used throughout. 
The GA lends itself to parallelization on a loosely coupled computer cluster (114).  In the 
present implementation, a “master” processor generates the chromosomes (compounds) 
for each generation, distributes n chromosomes apiece to N “servant” processors for 
docking and scoring, collects the results, and keeps a central list of all compounds tried 
and their scores. The servant processors decode the chromosomal representations into 
compounds, dock them, and return the scores to the master processor. The GA was 
implemented in parallel in the C++ programming language and using LAM/MPI 
libraries(115).  For the smaller virtual libraries of several thousand compounds (Section 
3.2.3), every compound in the virtual library was docked and scored. This allowed large 
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numbers of GA runs to be carried out efficiently by construction of a lookup table of 
chromosomal fitness scores.  This procedure is justified by confirmation of the 
consistency of the scores provided by the docking procedure used here (Section 3.3.1). 
For the larger libraries, N=60 processors were used, and each processor was sent n=4 
chromosomes at a time.  All results presented for the GA method are averages over 3 



























Figure 3.1: Chromosomal representation of a compound.  
(a) Each gene in a chromosome represents a substituent position. (b) Each allele of a gene 
represents a unique substituent in the corresponding substituent library. (c) Each 
























3.2.3 Additivity method 
3.2.3.1 Additivity approximation 
The additivity method is based upon the assumption that the difference in binding energy 
of two compounds in the combinatorial library can be approximated by a sum of the 
relative contributions from each substituent (116).  Thus, for a scaffold with four 
substitution sites, the binding energy Eijkl of a compound with substituents i ,j ,k ,l at each 
of the four sites, respectively, is estimated in terms of the binding energy of a reference 
compound E0000 with substituents 0,0,0,0, and the change in binding energy when each 
substituent 0 is replaced independently by i ,j , k and l, respectively:  
0000 000 000 0 00 0000 00 0 0000 000 0000( ) ( ) ( ) (ijkl i j k lE E E E E E E E E E≈ + − + − + − + − )  
Equation 3.1 
The success of the method depends upon the validity of this approximation. 
Continuing with the present example of a 4-site scaffold, the additivity approximation is 
applied by carrying out docking calculations for a reference compound (0000) and for all 
compounds that can be made by replacing one substituent in the reference compounds 
with another substituent; that is, compounds (i000), (0j00), (00k0) and (000l), where i, j, 
k and l take on all possible values other than 0.  This yields E0000 and all possible values 
of Ei000, E0j00, E00k0 and E000l. Thus, if there are 100 substituents for each of the four sites, 
then only 1+(4)(99)=397 docking calculations are needed to generate the quantities 
needed to estimate the binding energies of all 1004 compounds in the full library, via 
Equation 3.1.  
 70
3.2.3.2 Choosing compounds with the additivity method 
The top ranked compounds can be found by using Equation 3.1 to estimate the docking 
energy of all compounds, and then sorting them all, but this can lead to very large sorting 
calculations. A simple algorithm for identifying the top-ranked compounds was therefore 
devised. First, the substituents available at each site are sorted according to their energy 
scores. The top-ranked compound is simply the one with all of the top-ranked 
substituents. (See Figure 3.2, row 1, where the substituents’ indices are simply their 
ranks.)  The second-ranked compound, must be one of the following compounds: 
(2,1,1,1), (1,2,1,1), (1,1,2,1), or (1,1,1,2), (Figure 3.2, row 2), which can be identified by 
computing these compounds’ energies with Equation 3.1.  Here, the second compound is 
taken to be (1,1,2,1) (Figure 3.2, row 3).  The third-ranked compound is found similarly: 
four new compounds are formed by replacing each site of the second-best compound 
with the next best substituent (Figure 3.2, row 4), grouping the new compounds with all 
others that have previously been generated (Figure 3.2, rows 4-5), eliminating 
compounds that are clearly not candidates (Figure 3.2, red boxes) to form a reduced set 
(Figure 3.2, row 5), and choosing the best compound (here taken to be (1,2,1,1)) 
according to Equation 3.1 (Figure 3.2, row 6).  This process is repeated until the desired 
number of top-ranked compounds has been identified. Selected compounds from this 
method are then scored by docking and sorted to find the top-scoring compounds among 
them.  
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3.2.3.3 Pair wise additivity 
The additivity approximation described in Section 3.2.2.1 uses a single-site 
decomposition of the binding energy. Other decompositions also are possible and may be 
useful when there is reason to believe that substitution sites do not affect the binding 
energy independently.  For example, the substituents in the present four-site example can 
be grouped into two pairs, sites 1 and 2, and sites 3 and 4, and the energy of molecule 
(ijkl) can be estimated as  
0000 00 000 00 0000( ) ( )≈ + − + −ijkl ij klE E E E E E  
Equation 3.2 
This pair-wise approximation requires calculating the energies of all pair-wise 
substitutions at sites 1 and 2 (Eij00) and at sites 3 and 4 (E00kl).  If 100 substitutions are 
possible at each site, then evaluating these pair-wise energies requires (2)(992) or about 
20,000 dockings. This is more demanding than the single-site method, but may increase 
the accuracy of the energy predictions.  
3.2.4.4 Reference compounds 
The additivity approximation requires a reference compound, compound (0,0,0,0) in the 
4-site example.  Amprenavir (117) is used as the reference compound for amprenavir-like 
combinatorial libraries targeting HIV-protease. For the cathepsin system, no crystal 
structure is available with any compound based upon the combinatorial scaffold used 
here. Therefore, three different reference compounds were tried; all were drawn 
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arbitrarily from the small virtual combinatorial library.  For the larger virtual 
combinatorial library, only one arbitrarily chosen reference compound was used. 
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Figure 3.2: Combination of optimal substituents by single-site additivity method.  
Compound 1 is the combination of the best substituents for all sites. A first generation of 
compounds is generated by substituting each site with next best substituent, one at a time. 
In the present example, Compound 2 is taken to be the best of this generation. This 
iteration of substitution and selection continues until a predetermined number of 
compounds have been generated. The ranks of the substituents are represented by their 
indices, and the best compound from each generation is shown in bold font. The red 
blocks highlight pairs of compounds of which one (bottom) can trivially be eliminated in 
favor of the other (top).  
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3.2.3 Evaluation of additivity and GA methods 
In each comparison, the GA and Additivity methods were run for a preselected number of 
docking calculations. The number of dockings for the GA, NGA, is the product of the 
number of generations and the generation size. For the single-site Additivity method, the 
total number of dockings, Nadd, is given by . Here the 1 
accounts for docking the reference compound, N
1









sites is the number of substitution sites on 
the scaffold, ni is the number of candidate substituents at site i, and the summation 
represents the number of dockings required to generate the parenthesized quantities in 
Equation 3.1. Finally, reflects the additional work of computing the actual 
docking energies of the specific compounds predicted by Equation 3.1 to be top-scorers. 
The value of is chosen to make the total number of dockings for the 
Additivity method equal to N
tions
GA; hence .  
1
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For the smaller virtual libraries (Section 3.2.5), the compounds generated by the GA and 
Additivity methods are assessed by two measures. The first measure is the fractional 
recovery of the top-scoring 5% of compounds (“computational binders”) in the full 
virtual library. This quantity can be evaluated only if all compounds in the virtual library 
have been docked and scored, and therefore can be used only for the smaller virtual 
libraries (Section 3.2.5).  The second measure is the docking energies of the top 5% of 
the compounds in the designed library; this measure can be applied to the larger virtual 
libraries as well. For the large virtual libraries (Section 3.2.4), 6000 dockings were done 
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for both the GA and single-site Additivity method, and the distribution of the scores of 
the top 1000 compounds generated by the two methods were analyzed. The pair-wise 
additivity method was not tested for the larger virtual libraries, as it would have required 
more than the allotted 6000 dockings to generate the pairwise terms found on the right 























Figure 3.3: Combinatorial scaffolds. 
Amprenavir-like (top) and pepstatin-like (bottom) scaffolds were used in the construction 
of combinatorial libraries. Torsional freedom along the light brown, cyan and bright 
green colored bonds was restrained to ranges of 40, 60 and 180 degrees respectively. 
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3.2.4 Construction of compounds 
The docking calculations (Section 3.2.7) vary only the rotatable bonds and therefore 
require reasonable initial 3D structures of each candidate ligand as input. They also 
require molecular “topologies” comprising bonding information and force-field energy 
parameters, such as the Lennard-Jones parameters used in computing van der Waals 
interactions.  These structures and topologies were prepared as follows.  The initial 3D 
structure of the amprenavir-like and pepstatin-like scaffolds were drawn from the crystal 
structures 1HPV (117) and 1LYB (118), respectively. The initial 3D structures of all 
substituents (Section 3.2.5) drawn from the ZINC database (119) were taken as-is from 
Zinc. The initial 3D structures of the preoptimized substituents for the cathepsin system 
were prepared with Quanta (99). The initial 3D conformation of a compound in the 
virtual library was assembled when required by overlaying linking bonds and setting to 
ideal bond-length based on the atom types of connected atoms. “Ab initio”-like partial 
charges of the assembled compounds were generated with VCharge, an electronegativity 
equalization method parameterized to reproduce electrostatic potential fields computed at 
the 6-31G* level (120).  The resulting partial charges closely resemble those of 
CHARMM and AMBER for amino acids and nucleic acids (120). Dreiding force-field 
parameters were used for bond-torsions, and CHARMM parameters were used for 
Lennard-Jones interactions. 
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3.2.5 Substituent libraries 
3.2.5.1 HIV protease system 
Three sets of substituents were prepared, one with 100 candidate substituents at each site, 
and two with 15 candidate substituents at each site.  All carboxylic acids and primary 
amines were drawn from the building blocks collection of Zinc, and the carboxylic and 
amine groups were deleted and replaced with dummy linker atoms.  Thus, other 
functional groups could have been drawn from Zinc; the present choice was one 
convenient option.  A diverse set of 100 candidate substituents for each substituent site 
was drawn from these initial Zinc fragments, as follows. The  program Dragon (42) was 
used to compute, for each candidate substituent, the molecular weight, number of 
hydrogen bond donors, number of hydrogen bond acceptors, number of rotatable bonds, 
aromatic ring density, logP, and surface area.  The Euclidean distance, in the resulting 
descriptor space, was computed between each substituent of amprenavir and each 
candidate substituent and, for each substitution site, the 30 closest and 30 most distant 
candidates were chosen, along with 40 candidates of intermediate distance.  This 
procedure produces four different substituent libraries of 100 compounds, one library for 
each site of the amprenavir-like scaffold.   
Substituents for the small diverse library of size 15 fragments were drawn from this 
initial library of 100 diverse substituents, by choosing compounds at regular intervals of 
distance from the baseline amprenavir substituent.  A set of 15 preoptimized substituents 
for each scaffold site was formed by computing all 397 values of Ei000, E0j00, E00k0, and 
E000l (Section 3.2.2) for the 100 substituents, using amprenavir as the reference 
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compound (0000), and choosing the top-scoring 15 substituents at each site for further 
study.  
3.2.5.2 Cathepsin system 
A set of 25 candidate substituents preoptimized for the cathepsin target was drawn from a 
prior study (109); note that the same substituents were used at each position. A small 
diverse set of 25 candidate substituents was constructed from random compounds in the 
R1 fragment library of the amprenavir system (Section 3.2.5.1), along with 5 substituents 
from, the above mentioned, preoptimized set. A larger set of diverse substituents was 
constructed by supplementing the preoptimized 25 substituents with the 100 candidate R1 
substituents prepared for the HIV protease system, for a total of 125 possibilities at each 
site. 
3.2.6 Protein structures 
Candidate ligands for HIV protease and cathepsin were docked to PDB (33) structures 
1HPV (117) and 1LYB (118), respectively.  In both cases, the ligand and other 
nonprotein atoms were removed from the binding pockets, except for the flap water in the 
case of 1HPV.  The program Quanta (99) was then used to add all polar hydrogen atoms 
and their positions were optimized by energy minimization with only hydrogen atoms 
free to move.  
The structure of HIV protease and its substrates specificity has already been described in 
section 1.6. A brief description on cathepsin, its structure and its specificity is as follows. 
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Cathepsin D is a mammalian aspartic protease found primarily in lysosomes and 
suspected of involvement in a variety of diseases such as cancer, Alzheimer’s (121) and 
muscular dystrophies (118). At 366 residues, it is somewhat larger than HIVP. Its 
crystallographic structure reveals a fold similar to that of other mammalian aspartic 
proteases, such as renin, chymosin and pepsin (118). It also shares a close-packed core of 
conserved, hydrogen-bonded polar residues. It structure can be divided into an N-
terminal domain, a C-terminal domain, and an interdomain connecting both terminals. 
The N- and C-terminal domains each contribute one aspartic acid to the active site, which 
lies in the deep cleft formed by both the domains (Figure 3.4) (122).  This cleft is wider 
than that of renin, so cathepsin can bind larger substrates and inhibitors (118). 
Cathepsin D can bind to substrates 9 amino acids long, which occupy sites from S5 to S3’ 
in the active site. Its substrate specificity is not yet fully characterized, as its role in 
human physiology is not completely understood. Like HIVP, it prefers hydrophobic 
residues around the scissile bond (122). It also has a strong preference for a hydrophobic 
residue in the P2 site of the substrate, but can still accommodate hydrogen bonding 
residues at this location. However, the P2 site does not accept cationic amino acids.  The 
presence of Met in the S2 subsite may help explain its especially strong preference for 
hydrophobic substrate residues, relative to other aspartic proteases. 
Binding of the inhibitor pepstatin to cathepsin D induces small structural changes in the 
“flap region” (residues 72-87, Figure 3.5) and in a proline-rich loop (Figure 3.5) (118). In 
contrast, the flap regions of both monomers of HIVP are believed to move substantially 
on binding (section 1.1.6.2). Numerous hydrogen bonds between the main chain atoms of 
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bound pepstatin with the active site residues stabilize the complex. In addition, the 
hydroxyl of the central statine group of pepstatin forms hydrogen bonds with the catalytic 
aspartates much as the core hydroxyl of most HIVP inhibitors interact with the catalytic 












Figure 1: Various domains of human Cathepsin D. 
Figure 3.4: Cartoon representation of Cathepsin D 
Blue: N-terminal domain. Green: C- terminal domain. Orange: Interdomain. Catalytic 



















Figure 3.5: Flap region and proline loop of Cathepsin D 
Blue: N-terminal domain. Green: C- terminal domain. Orange: Interdomain. Red: Flap 
region (residues 72 to 87). White: Proline loop (residues 312 to 317). Catalytic aspartates 
are shown in ball and stick model. Inhibitor, pepstatin is shown in licorice model.  
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3.2.7 Docking and scoring 
Candidate ligands were docked and scored with VDock (85, 86), using a distance-
dependent dielectric constant with a coefficient of 4.  In order to accelerate convergence, 
the scaffold of each compound was restricted to lie near the pose observed for amprenavir 
in the HIV protease tests and pepstatin in the cathepsin tests. The translational box had 
dimensions of 1 and 5 angstroms for HIV protease and cathepsin systems respectively. 
Rotation of amprenavir scaffold was restricted to 30 degrees, where as the cathepsin 
scaffold was not rotationally restricted. Torsional freedom was restrained for 6 and 4 
dihedrals for amprenavir and cathepsin systems respectively (see Figure 3.5 for torsional 
restraints). One thousand ligand conformations were tested during both of the  “hunt” and 
“fine tune” phases of the protocol (85). Each docking run generated 20 minimized 
conformations and ten independent docking runs were performed for each ligand. The 
lowest-energy conformation of the resulting 200 conformations was chosen to be the 
predicted binding pose and its energy was recorded as the compound’s score. Scoring of 
a compound with this protocol takes approximately 6 minutes on a commodity computer. 
3.3 Results 
The results section is organized as follows. The first subsection deals with the 
reproducibility of the docking energy scores. The second subsection analyzes the 
distribution of predicted binding affinities of smaller virtual libraries, which may help in 
the understanding of results in the following subsections. The third subsection evaluates 
the ability of Additivity methods to predict the docking energy scores. The last two 
subsections compare the Additivity method with the GA, based upon the retrieval of 
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computational binders and on the docking energies of the top-scoring compounds that 
each method provides. 
3.3.1 Convergence of VDock 
The reproducibility of the VDock scores was assessed for both the HIV protease and 
cathepsin systems by docking and scoring 1000 compounds with randomly picked 
substituents, using the docking protocol described in Section 3.2.7.  Figure 3.6 compares 
the score from one scoring run of 10x20=200 dockings with the score from a second, 
equivalent run started with different random number seeds.  The two scores agree 
reasonably well for the lowest energy compounds (lower curve in each graph), while 
somewhat greater scatter is evident for higher-energy compounds (upper curve in each 
graph). Presumably the tightest binding compounds are the easiest to fit repeatedly into a 
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Figure 3.6: Evaluation of the consistency of the docking calculations. 
Histograms of the difference in docking energy score from two independent calculations 
on the same compound, for HIV protease with 1000 diverse compounds (top) and 
Cathepsin with 1000 preoptimized compounds (bottom). Upper curve in each graph is for 
all 1000 compounds; lower curve in each graph is for compounds with both energy 
evaluations less than -50 kcal/mol. 
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3.3.2 Characterization of compound libraries 
The distribution of energy scores of the four smaller libraries is presented in Figure 3.7.  
The two libraries constructed of preoptimized substituents (left-most peaks in the figure) 
extend to scores as low as about -75 kcal/mole, with a peak at about -65 and tails to about 
0 kcal/mol.  The random cathepsin library extends to about -70 kcal/mol and peaks at 
about -48 kcal/mol, while the energies of the random amprenavir-based library are very 
broadly distributed, extending to about -65 kcal/mol and with a very wide peak at about -
20 kcal/mol. Analysis of these distributions help in the explanation of some of the results 
obtained in tests of the Additivity and GA methods.  
 






















Figure 3.7: Distribution of docking energy scores for the smaller libraries.  
Fraction of library compounds in energy bins of width 2 kcal/mol. HIVP system: heavy 
lines. Cathepsin system: thin lines.  Random libraries: solid lines.  Preoptimized libraries: 
dashed lines.  
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3.3.3 Assessment of additivity 
The numerical accuracy of the additivity approximation was assessed here by comparing 
the docking energies predicted with the Additivity approximation (Epred) with those 
calculated for the same compounds by docking and scoring them (Ecalc).  The analysis 
was done for the smaller compound libraries (Section 3.2.5), which are amenable to 
exhaustive evaluation.  Figures 3.8, 3.9 and 3.10 summarize the results with histograms 
of Ecalc -Epred. Perfect additivity would correspond to histograms sharply peaked at zero; 
in fact, all of the histograms peak near zero, but the width of the histograms indicates 
substantial deviations from perfect additivity. These deviations in the additivity could be 
due to the differences in the positioning of the substituents or even the scaffold itself 
between the predicted and calculated poses. Examples of such cases, where the Additivity 
could fail are shown in Figure 3.11. It is also important to recognize that some of the 
deviations from additivity undoubtedly result from the imperfect reproducibility of the 
docking scores themselves, for compounds with poor predicted binding affinity: the 
additivity graphs may be compared with the reproducibility graphs in Figure 3.6 
Interestingly, the Additivity approximation tends to become more accurate (sharper 
peaks) for compounds with better energy scores.  This is clear from two types of 
comparison within the graphs. First, the distributions are sharper for the preoptimized 
libraries (bottom of Figure 3.8, and all of Figure 3.10), than for the diverse libraries (top 
of Figure 3.8 and all of Figure 3.9); Second, the lower family of curves in each graph, 
which shows the distribution of errors for the lowest-energy compounds in each library, 
tends to be sharper and centered more precisely at zero.  This observation may result, in 
 86
part, from the great reproducibility of the docking energies of lower-energy compounds 
(Figure 3.6).   
The accuracy of single-site (heavy solid lines) versus pairwise additivity (thin lines) can 
be assessed by comparing the curves within each family.  It is evident that including 
pairwise interactions explicitly with the pairwise additivity method does tend to yield 
narrow error distributions that are centered more closely on zero.  Moreover, pairing 
nearest-neighbor substituents (solid thin lines) tends to yield the greater improvement 
than other pairings (thin dashed lines).   
Finally, Figures 3.9 and 3.10 provide information on the sensitivity of the results to the 
choice of reference compound; i.e., compound (0000) in Equations 3.1 and 3.2.  
Although the overall results are similar for different reference compounds, based upon 
comparison of the top, middle and bottom graphs, it can also be seen that different 
baseline compounds cause the distributions to skew differently.  For example, the 
calculated energies tend to be more negative than predicted in the top graph of Figure 
3.10, but the opposite trend is observed in the bottom graph of Figure 3.10.  Potential 
mechanisms by which the choice of reference compound may shift these distributions are 
considered in the Discussion (section 3.4). 
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Figure 3.8: Accuracy of Additivity approximations for HIV protease system. 
Histograms of differences between calculated and predicted energies scores of 
compounds, with 2 kcal/mole bins, for single-site Additivity model (heavy solid), and 
Pairwise Addivitity models based upon sites R1R2-R3R4 (dashed), R1R4-R2R3 (dashed), 
and R1R3-R2R4 (thin solid).  Diverse fragment libraries (top), showing histograms for all 
compounds (upper family of curves) and for compounds with predicted and calculated 
energies less than -50 kcal/mol. Preoptimized fragment libraries (bottom), showing 
histograms for all compounds (upper family of curves) and for compounds with 
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Figure 3.9: Accuracy of Additivity for Cathepsin system with diverse library. 
Histograms of differences between calculated and predicted energies scores of 
compounds, with 2 kcal/mole bins, for single-site Additivity model (heavy solid), and 
Pairwise Addivitity models based upon sites R1-R2R3 (dashed), R1R3-R2 (dashed), and R1-
R2R3 (thin solid), for three different reference compounds (top, middle, bottom).  In each 
graph, the upper curves are for all compounds, and the lower curves are for compounds 
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Figure 3.10: Accuracy of Additivity for Cathepsin system with preoptimized library. 
Histograms of differences between calculated and predicted energies scores of 
compounds, with 2 kcal/mole bins, for single-site Additivity model (heavy solid), and 
Pairwise Addivity models based upon sites R1-R2R3 (dashed), R1R3-R2 (dashed), and R1-
R2R3 (thin solid), for three different reference compounds (top, middle, bottom).  In each 
graph, the upper curves are for all compounds, and the lower curves are for compounds 

























































Figure 3.11: Examples of failure for the Additivity method.  
(a) Differences in the orientation of substituents at R1 and R3 positions in the HIVP 




3.3.4 Retrieval of computational binders 
The Additivity and GA design methods were evaluated according to their success in 
recovering the computational binders in the smaller virtual libraries; i.e., the top-scoring 
5% of compounds in each library.  Figures 3.12 and 3.13 graph the fraction of 
computational binders recovered as a function of the number of docking runs.  The 
results of hypothetical ideal and random design methods are included for comparison.  
As expected, both the Additivity (red and dashed lines) and GA methods (green) 
consistently outperform random compound selection (cyan) and underperform ideal 
(black).   The performance of both methods is better for the diverse libraries (Figures 
3.12a and 3.13a-c), than for the preoptimized libraries (Figures 3.12b and 3.13d-f).  This 
probably is a consequence of the fact that the diverse libraries have far fewer high-
scoring compounds than the preoptimized libraries (Figure 3.6), so the computational 
binders are easier to distinguish from the others compounds.  This also helps explain why 
better results are obtained for the diverse HIVP library than for the diverse Cathepsin 
library: the latter contains a higher concentration of tight-binding compounds.  
Interestingly, the single-site Additivity method consistently outperforms the GA, 
although the degree to which it is favored is case-dependent. Its advantage is most 
marked for lowest-scoring libraries; i.e., for the random Cathepsin libraries and especially 
for the diverse HIVP libraries, as reflected in the energy histograms in Figure 3.6. The 
pairwise Additivity calculations (dashed lines) give mixed results.  For the HIV protease 
system, they tend to outperform single-site additivity.  Particularly good results are 
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obtained with the pairing that accounts for interactions between the nearest-neighbor 
substituents, R1R3-R2R4 (gold dashed line).  This is consistent with the enhanced 
predictivity of this pairing evident in Figure 3.8.  It is worth noting that the pairwise 
calculations require more docking calculations as overhead.  For example, evaluating all 
the component terms E000, Ei,00 and E0,jk for the R1-R2R3 pairing in the Cathepsin series, 
with 25 candidate substituents at each site, requires 1 + 24 + 242 = 601 dockings at 
minimum.  Single-site Additivity for the same library requires only 1 + 3(24)=73 
dockings. This difference accounts for the fact that the pairwise curves start further to the 
right than the single-site and GA curves. This higher overhead may also account for the 
fact that the yield of computational binders for a given number of dockings tends to start 
low. The greater accuracy of the pairwise predictions (Figures 3.8-3.10) then accounts for 
the fact that the pairwise curves then tend to rise above the single-site curves.   
For Cathepsin, the consequences of changing from one reference compound to another 
can be assessed by comparing across Figures 3.13 a,b,c for the diverse library, and across 
d,e,f for the preoptimized library.  The results are fairly uniform, except that the single-
site and the two pairings other than R1-R2R3 pairing (gold dashed) perform worse for the 
diverse library with reference compound one (Figure 3.13a) than for the other reference 
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Figure 3.12: Retrieval of computational binders for HIVP system  
Fraction of computational binders retrieved as a function of the number of dockings, for 
HIV protease system, with small diverse (a) and preoptimized (b) substituent libraries.   
Ideal: black.  Random: cyan.  GA: green.  Single-site Additivity: red.  Pairwise additivity, 
dashed, with R1R3-R2R4 gold; R1R4-R2R3 red;  R1R2-R3R4 brown.  
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Figure 3.13: Retrieval of computational binders for Cathepsin system 
Fraction of computational binders retrieved as a function of the number of dockings, for 
Cathepsin protease system, with small diverse (a, b, c) and preoptimized (d, e, f) 
substituent libraries, with different reference compounds.   Ideal: black.  Random: cyan.  
GA: green.  Single-site Additivity: red.  Pairwise additivity, dashed, with R1-R2R3 gold; 
R1R2-R3 red;  R1R3-R2 brown. 
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3.3.5 Docking energy scores of top compounds  
The performance of the Additivity and GA methods was also evaluated based upon their 
ability to generate compounds with good energy scores. This measure does not require 
exhaustive docking of the virtual library and so can be used for the larger virtual libraries 
as well.  Results are presented here for both the smaller and larger libraries.  
3.3.5.1 Smaller combinatorial libraries 
The average docking energy of the top-scoring 5% of compounds found by each method 
are graphed against the number of dockings for the HIVP (Figure 3.14) and Cathepsin 
(Figure 3.15) systems.  Graphs for theoretically ideal and random compound selection are 
again included, for comparison.  Data are provided for both the diverse (left) and 
preoptimized (right) small libraries.  As expected, the gap between ideal and random is 
larger for the diverse than for the preoptimized libraries, and the best energies (ideal 
graphs) are more favorable in the preoptimized libraries. As expected, both the Additivity 
and GA methods yield much better results than random selection, yielding curves that lie 
fairly close to ideal, more so, apparently, than for recovery of computational binders 
(Section 3.3.4), presumably because the libraries contain a significant number of 
compounds that are not computational binders but that have energies similar to those of 
the computational binders (Figure 3.7). 
Overall, the single-site Additivity method again tends to outperform the GA especially 
for the more diverse libraries, yielding sub-libraries with generally better (more negative) 
binding scores for a given number of dockings.  The pairwise Additivity calculations 
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again yield a mixed picture.  It is worth noting that the energy ranges in the graphs are 
rather small, especially for the preoptimzed libraries, making fine distinctions uncertain.  
 


























































Figure 3.14: Mean docking energy of the top 5% of designed compounds, for HIVP 
system  
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Figure 3.15: Mean docking energy of the top 5% of designed compounds, for 
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(a) Random fragment libraries. (b)Preoptimized fragment libraries. See previous legends 
for symbols. 
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3.3.5.2 Larger combinatorial libraries 
The distribution of docking energy scores of the top 1000 compounds found by each 
design method for the larger virtual combinatorial libraries are given in Figure 3.16. In 
spite of the differences in the systems, the two sets of graphs are remarkably similar.  The 
Additivity method yields very few poor compounds, but the peaks of the GA distributions 
are shifted to lower energies than those of the Additivity distributions. Over the entire 
distribution, the Additivity method seems to yield a higher number of compounds with 
better docking energy scores than the GA. However, the docking energy scores of top 
compounds from GA are better than from the Additivity method. The differences in the 




































































Figure 3.16: Distribution of docking energy scores of top 1000 compounds  
(a) HIV protease system. (b) cathepsin system. Docking energy scores are given in 
kcal/mol. Bright green: GA and Red: Single site additivity method  
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3.4 Discussion 
The present study demonstrates that both the Additivity approximation and a GA can 
strongly enhance the yield of high-scoring compounds in a combinatorial sublibrary, 
relative to random selection, when a structure-based docking method is used to score 
compounds.  Thus, either method may be used in real-world library design.  Overall, the 
Additivity method is found to perform as well as or better than the GA method, when 
both are allowed the same number of dockings to optimize a combinatorial sublibrary.  
One reason for this may be that, whatever its weaknesses, the Additivity method has the 
strength of being guaranteed to try every candidate substituent at each site; in contrast, it 
is highly unlikely that the GA will try every substituent at each site, when a large library 
is studied.  Therefore, the GA risks missing good substituents.  On the other hand, the GA 
has the potential advantage of identifying specific combinations of substituents that work 
particularly well because of their sizes and charges, for example, are mutually 
complementary.  Another advantage of the Additivity method is that it is essentially 
trivial to implement, whereas the GA is relatively complex piece of software. 
All of the methods tend to yield better results for the HIVP system than for the Cathepsin 
system. One reason may be that the HIVP substituents are more diverse and the 
compounds’ energies therefore are spread more widely, making it easier to pick out the 
top scorers.  Another reason undoubtedly is the unanticipated flipping of some 
compounds in the Cathepsin library.  Such flips cause a given substituent to make a 
different energy contribution depending upon the part of the binding site with which it 
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interacts.  Note that the GA results also depend to some degree upon additivity: the 
crossing-over two compounds will yield a new and better compound only if the good 
substituents of the two compounds are still good when they are brought together in one 
compound.  In general, both the Additivity and GA methods are expected to perform best 
when the combinatorial scaffold adopts a rather uniform pose within the binding site.  
The pairwise approach is logical and does improve results in a number of cases, 
especially for the HIVP system, and especially when nearest-neighbor substituent sites 
are paired.  Its weaker performance for the Cathepsin system may be a consequence of 
the flipping of some compounds, which limits the overall accuracy of additivity.  The 
pairwise method does impose a higher computational overhead than the single-site 
method because it requires calculation of energy contributions from all pairs of interest, 
not just all single substituents.  In a real-world application, knowledge that two 
substituents are likely to contact each other in the binding site would argue in favor of 
pairing these substituents. The likely benefit of the pairing could be evaluated by test-
calculations of the sort described in Section 3.2.3.3.   
The chief exception to the rule that the Additivity method is superior to the GA is for the 
large, diverse Cathepsin library, where the GA does somewhat better than single-site 
Additivity at identifying the highest scoring compounds.  The reasons for this are still 
uncertain, but may have to do with the tendency of some Cathepsin ligands to flip in the 
binding site.  On the other hand, flipping should also pose problems for the GA.  It will 
be interesting to repeat some of these calculations with a restraint on the scaffold that will 
prevent flipping.  Another possible explanation is that there may simply be more 
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nonadditivity in the Cathepsin library, even in the absence of flipping, due to interactions 
between substituents.  The pairwise Additivity approach is one way to alleviate this 
problem, but it would be time-consuming to run the >10,000 dockings need to run a full 
additivity analysis of one pair of substituents the large Cathepsin library.  The time could 
be cut constructing and docking pairwise combinations of only the most promising 
substituents from a single-site analysis. 
Previous applications of the Additivity concept have used single-site substitutions to pick 
the most promising substituents at each site, and then formed libraries by combining 
them.  The present implementation goes beyond these methods by using Equation 3.1 and 
3.2 to predict the binding energies of the various combinations.  This quantitative 
approach should be better in the case where the energy contributions of the various 
substitutions are not uniformly distributed.  For example, if the next-ranked two 
substituents at R1 both give excellent binding energies, but neither of the next-ranked two 
substituents at R2 gives good energies, and then expanding the library with the two 
substituents at R1 should be better than expanding it by adding one at R1 and one at R2.  
The quantitative approach taken here also leads directly to the pairwise Additivity 
method, which often yields better predictions than the single-site approach. 
It is worth noting that using different docking software could influence the results of this 
analysis. For one thing, VDock uses a pairwise additive energy function, and this clearly 
favors the Additivity method, as well as the GA.  Incorporation of a solvation model that 
is not pairwise additive, such as the Poisson-Boltzmann (123, 124) or Generalized Born 
(124) model, might degrade the performance of these methods.  On the other hand, the 
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non-additivity of these solvent models may not be severe for a ligand in a highly 
desolvated binding site.  A second issue is the imperfect reproducibility of the docking 
calculations, which limits the potential accuracy of the Additivity approximation.  It 
would be interest to explore both of these issues through tests with different docking 
algorithms and scoring functions.   
Ultimately, a more fundamental and interesting question is how well the Additivity 
approximation holds in reality; that is, how well the measured affinity of a new 
compound can be predicted based upon additive contributions of its substituents.  
Somewhat surprisingly, this issue does not appear to have been addressed in the 
literature; it is therefore being addressed in a separate project, to be described elsewhere. 
3.5 Conclusions 
The present study introduces a quantitative Additivity method for the efficient structure-
based design of combinatorial libraries. The method provides for a purely single-site 
additivity approximation, as well as a more sophisticated pairwise approach that allows 
for interactions between substituents, but comes at a greater computational cost.  These 
Additivity methods are compared with a GA design method in various situations.  Both 
approaches are much better than random compound selection, and the Additivity method 
tends to outperform the GA.  Not surprisingly, it is harder to identify the top-scoring 
compounds in a library of compounds that all score well; and when the combinatorial 
scaffold flips orientation in the binding site, predicted affinities become less reliable. 
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Chapter 4. Design, Synthesis, and Biological 
Evaluation of HIV-1 Protease Inhibitors with 
Broad Specificity 
4.1. Introduction 
The use of HIV protease inhibitors significantly reduced the mortality and morbidity rate 
in AIDS patients (25, 92, 93), but the emergence of resistance and cross resistance to the 
existing protease inhibitors has become a major threat in AIDS therapy. There is a thus a 
need for inhibitors with broad specificity against existing treatment-resistant strains, and 
without vulnerability to potential future mutations.  One approach to developing such 
inhibitors may be to design compounds that make only substrate-like interactions with the 
binding site, so any mutation that weakens binding of the inhibitor should also weaken 
binding of the substrate, and thus lead to reduced enzymatic activity and a less viable 
virus. 
Crystallographic studies of complexes of HIV-1 protease with its substrates have shown 
that, despite the differences in their amino acid sequences, the various substrates fill a 
rather uniform volume, with a toroidal shaped component on the unprimed side of the 
cleavage site and an extended shape on the primed side, (95, 125). This consensus 
substrate volume differs significantly from that occupied by existing clinical inhibitors in 
the binding site, and residues near locations where inhibitors extend outside the substrate 
volume were observed to be loci of resistance mutations. These observations led to the 
hypothesis that the selective recognition of substrates by treatment-resistant variants of 
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HIVP is attributable to the differences in the shape of bound substrate versus inhibitors., 
and that inhibitors that fit within the border of the consensus volume, termed the 
“substrate envelope”, may be less susceptible to resistance mutations (96). Chapter 2 
provides retrospective data that support the validity of this substrate envelope hypothesis.  
The present chapter describes a prospective evaluation of the hypothesis through the 
design and experimental characterization of a combinatorial library of HIV-1 protease 
inhibitors that aim to achieve high binding affinity while fitting the substrate envelope. 
The library is based upon a hydroxylethylamine scaffold (Figure 4.1), because it is a part 
of amprenavir, an existing HIVP inhibitor which has been shown to fit well within the 
substrate envelope. The ability of this scaffold to make key hydrogen bonds with HIV 
protease through the flap water and the catalytic aspartates, along with considerations of 
synthetic feasibility, also favored its selection. The present study also examines the 
consequences of the two accessible inversion geometries of the sulfonamide nitrogen 
(126) upon the computational results and predictions.  Two of the designed compounds 
are found to bind to wild type protease with nanomolar affinity, and to retain substantial 
affinity against a panel of clinically relevant resistance mutations. These results support 














Figure 4.1: Combinatorial scaffold showing the restrained torsions.  
Torsional freedom along the blue, magenta and red colored bonds is restrained by ±20, 
±30 and ±90 degrees respectively. 
4.2 Methods 
This section is organized as follows. The first subsection details the design methodology, 
and the next two subsections give a brief overview of screening and crystallographic 
studies, which were kindly provided by our collaborators. The last subsection describes 
the analysis of the effect of sulfonamide inversion on the docking.  
4.2.1 Computational methods 
4.2.1.1 Scaffold selection  
The ideal characteristics of a combinatorial scaffold are as follows: 1) Synthetic 
feasibility and ability to provide diverse chemistry through a number of attachment 
points. 2) Ability to establish key interactions with the target protein. The second feature 
not only improves the affinity of compounds in the combinatorial library but also helps 
limit the movement of scaffold in the active site. This restriction can accelerate the 
structure-based virtual screening process by reducing the computational time involved in 
conformational search (Section 4.2.1.4)(78). We selected the hydroxylethylamine 
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scaffold shown in Figure 4.1, based on the above criteria, as well as the scaffold’s ability 
to position the three variable substituents, R1, R2 and R3, within the substrate envelope. 
Synthetically, R1 substituents require a carboxylic group, R2 substituents require a 
primary amine, and R3 substituents require a sulfonylhalide.  The initial 3D conformation 
of the scaffold was prepared from the crystal structure of amprenavir in complex with 
HIV protease (1HPV)(127) in structure definition file (SDF) format. The sulfonamide 
geometry of the scaffold thus was that found in 1HPV.  
4.2.1.2 Substituent libraries 
Initial designs used functional groups from the “all purchasable” subset of the Zinc 
database (119). This subset was sorted by functional group, carboxylic acids and primary 
amines were extracted for the R1 and R2 positions, respectively. Sulfonyl halides were 
collected from the Sigma-Aldrich and Maybridge catalogs. All candidate substituents 
were restricted to have fewer than 12 non hydrogen atoms, in order to favor the 
construction of small compounds that are likely to fit within the substrate envelope. This 
restriction yielded approximately 7000, 1200 and 350 compounds for the R1, R2 and R3 
positions respectively. Starting 3D conformations of the substituents available in Zinc 
were used as-is; the rest were constructed with the program Quanta. The chemical 
components (carboxylic acids, amines and sulfonyl halide) were tagged as belonging to 
R1, R2 and R3, respectively, and the functional groups were then removed and replaced 
with linker atoms connected by pseudobonds, to facilitate compound construction, as 
described below. 
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4.2.1.3 Construction of compounds 
A new program, termed “Dovetail”, was used to build in-silico combinatorial libraries in 
3D conformations in SDF format from initial 3D structures of the scaffold and 
substituents. Dovetail builds a combinatorial compound by matching the substituent sites 
and the corresponding functional groups for the desired compound, overlaying a 
pseudobond with the terminal substitution bond in the scaffold, deleting the redundant 
linker atoms, forming new bonds joining the substituents to the scaffold, and assigning 
force-field parameters to the resulting compound. “Ab initio”-like partial charges of the 
resulting compounds are generated with VCharge, an electronegativity equalization 
method parameterized to reproduce electrostatic potential fields computed at the 6-31G* 
level (120). Lennard-Jones parameters are assigned from CHARMm (128) atom types, 
and bond-torsions parameters are drawn from the Dreiding force field (129).  
4.2.1.4 Docking and scoring 
The program VDock was used to dock and score the combinatorial compounds, using a 
distance-dependent dielectric constant with a coefficient of 4. This docking program uses 
three pre-computed grids: an electrostatic grid, an attractive Lennard-Jones grid and a 
repulsive Lennard-Jones grid, which allow the rapid calculation of the interaction of the 
ligand with a fixed conformation of the protein (85). Combinatorial library compounds 
were docked to 1HPV (127). This protein structure was superimposed on 1HSG (100), to 
place the docked conformations in the same reference frame as that of the substrate 
envelope grid (section 4.2.1.5). The receptor structure was prepared by removing ligand 
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and other non protein atoms from the binding pockets, except for the flap water.  The 
program Quanta (99) was then used to add all polar hydrogen atoms and their positions 
were optimized by energy minimization with only hydrogen atoms free to move.  
In order to compute the interaction energy between a receptor and a ligand, VDock 
should identify the most stable bound conformation of the ligand and compute the energy 
for this bound conformation. Identification of the low energy conformations from a large 
conformational search space can be computationally challenging. We accelerated the 
search by restricting the movement of the combinatorial scaffold, so that it lies close to 
the binding pose observed in 1HPV. As the scaffold forms key interactions with the 
catalytic aspartates and the flap water, which beautifully anchor it in the active site, 
restraints on its movements in our docking and scoring calculations can be justified. The 
translational movement of the scaffold was restricted to ±1 Å in each axis, and the 
rotation was restricted to ±30 degrees. Movement along six dihedrals in the scaffold was 
also restrained, as shown in Figure 4.1. Ten independent docking runs were performed 
for each ligand, with each docking run resulting in an output of 20 docked conformations. 
The lowest energy conformation among the 200 generated conformations was taken as 
the predicted binding pose and the energy as the predicted binding affinity. Scoring of a 
compound with this protocol takes approximately 6 minutes.  
4.2.1.5 Evaluation of substrate envelope fit 
Candidate inhibitors were also scored for their fit within the substrate envelope using a 
grid based method described in Chapter 2. Briefly, a cubic three-dimensional grid with 
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side-length 10 Å and grid spacing 0.2 Å was centered on the active site of HIV protease, 
1HSG (100). Six HIV protease substrates (1F7A, 1KJ4, 1KJ7, 1KJF, 1KJG, 1KJH (37)) 
and their symmetry-operated structures, for a total of 12 substrate structures, were 
superimposed on 1HSG, based upon the coordinates of backbone atoms. Each grid point 
was assigned a value of 0 and then incremented by 1 for every substrate structure 
containing the grid point. A grid point is considered to be contained by a substrate if it 
lies within the CHARMm (128, 130) van der Waals radius of any non-hydrogen atom of 
the substrate.  
The fit of a ligand to the substrate envelope is computed as follows. The docked ligand 
conformation is overlaid laid on the substrate envelope grid, and the effective volume of 
the ligand outside the substrate envelope, Vout, is computed by summing the values of the 
grid points gijk that lie within the van der Waals volume of the inhibitor, normalizing the 
sum by 12, and converting to a volume by multiplying by the 0.008 Angstrom3 volume of 







V g≡ −∑  
Equation 4.1 
Here “inside” implies that the sum runs only over grid points ijk that lie within the van 
der Waals volume of the inhibitor.  
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4.2.1.6 Selection of compounds 
Our two design criteria, high predicted binding affinity and the fit to the substrate 
envelope were combined to give one single score, to prioritize our compounds. This was 
done with Z-scores, since energy and Vout scores have different units (131). For a given 
distribution, the Z-score of an individual with observed value  is iX
σ/)(
−




X  and σ  are the mean and standard deviation of the distribution respectively. For 
each candidate inhibitor, the Z-scores of its VDock energy and Vout were computed in the 
context of the distribution of energies and substrate volumes of all candidate inhibitors 
studied.  The two Z-scores were then simply averaged to arrive at a composite figure of 
merit for the compound. 
4.2.1.7 Combinatorial library design 
An exhaustive virtual combinatorial library would comprise approximately 3 billion 
compounds, based upon all the candidate substituents described in section 4.2.1.2. 
Docking and scoring of all these compounds is not practical, as it takes approximately 6 
minutes per compound. This problem was addressed as follows.  First, single-site 
Additivity analysis was carried out, with Amprenavir as the reference compound; see 
Chapter 3 for methodological details and validation of this approach.  The candidate 
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substituents at each site, R1, R2 and R3, were ranked by the combined Z-scores of 
VDock energy and Vout, according to the single-site results, and the top 150 candidates at 
each site were identified.  Multiple Genetic Algorithm calculations (Chapter 3) were 
carried out with these 150 candidates at each position, with the combined Z-score as a 
fitness function, and substituents at each position that occurred repeatedly in the top 100 
compounds were identified and discussed.  Unsuitable substituents, such as symmetric 
amines, and ones that proved to be unavailable, were eliminated.  Further substituents 
were eliminated in order to narrow attention to fully combinatorial sublibraries.  
Ultimately, a fully combinatorial library of 27 compounds was proposed, and 26 of these 
compounds were synthesized and tested. 
4.2.2 Enzymatic assays 
The dissociation constant of an enzyme inhibitor, Ki, can be measured by the change in 
the rate of catalysis in its presence. The change in the consumption of substrate or in the 
generation of product over time gives the change in rate of catalysis. There are several 
ways to measure this change in the velocity of the reaction. One such method is the 
fluorometric assay in which a difference in the fluorescence of substrates or products is 
detected.  Here, Ki values were measured with fluorescence resonance energy transfer 
assays. A protease substrate was terminally labeled with a florescence energy transfer 
donor and acceptor. On proteolysis, the fluorescence of the fluorophore is recovered, and 
can be monitored at suitable excitation and emission wavelengths. The proteolysis rate is 
thus reflected by rate of evolution of fluorescence emission, andKi is obtained by 
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nonlinear regression fitting to the plot of enzyme velocity as a function of inhibitor 
concentration. 
The designed compounds were screened for their binding affinity not only to the wild-
type HIV protease but also for a panel of proteases that have clinically relevant sets of 
mutations: M1 (D30N/L63P/N88D), M2 (L10I/G48V/I54V/L63P/V82A) and M3 
(L10I/L63P/A71V/G73S/I84V/L90M)).  
4.2.3 X-ray crystallography 
X-ray crystallography was used to determine the structures of selected protein-ligand 
complexes. Crystals of protein-ligand complexes were prepared by the hanging drop 
vapor diffusion method. In this method, a droplet of concentrated solution of protein and 
precipitating agent is applied to a glass cover slip, which is then inverted so as to suspend 
the droplet above a larger reservoir of solution with higher concentration of precipitating 
agent. Over time, water in the droplet evaporates and then condenses in the reservoir, 
leading to a gradual increase in concentration of precipitant in the suspended droplet, and 
hence to crystallization of the protein-ligand complex.  The protein crystals are harvested, 
cooled with liquid nitrogen, and used to generate X-ray diffraction patterns which are 
reocorded and analyzed with commercially available software to provide the 3D structure 
of the complex to atomic resolution.  
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4.2.4 Analysis of the effect of sulfonamide geometry on the predictions 
The combinatorial scaffold has a sulfonamide nitrogen which is capable of inversion, 
resulting in two different conformations. As our docking program does not try alternate 
conformations of this nitrogen during the docking calculations, the sulfonamide geometry 
is held fixed throughout the calculations.  The choice of conformation was uncertain 
because there were only ten PDB structures of HIVP with ligands containing such a 
sulfonamide moiety, three of them with 1HPV-like geometry, and 7 with the alternate 
geometry. As we used the receptor structure from 1HPV, we assigned the corresponding 
sulfonamide geometry to the combinatorial scaffold during the design process. However, 
the crystal structures of the designed ligands showed them to adopt the other sulfonamide 
geometry. This observation led to retrospective analysis of the effect of the sulfonamide 
geometry on the docking calculations. 
The analysis was carried out by docking the designed ligands with both sulfonamide 
geometries into two crystal structures of HIV protease, 1HPV and KB60 (Schiffer and 
coworkers, unpublished) which were solved with sulfonamide-containing ligands having 
opposite nitrogen geometries.  In the present paper, the sulfonamide geometry found in 
KB60 will be referred to as the “inverted” geometry.  These calculations provide 
information regarding the direct influence of the sulfonamide geometry on ligand 
confrormation, and also regarding any indirect influence of the sulfonamide geometry 
that may result from its effect on the conformation of the protein. The docking 
calculations were performed as detailed in section 4.2.1.4, and the root mean square 
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distance (RMSD) between the non-hydrogen atoms in the predicted and crystallographic 
structures were used to compare the docking results. 
4.3 Results  
This section presents results of the computational design process, provides the binding 
affinities of the designed compounds, then analyzes the ligand-protein interactions of the 
two highest-affinity inhibitors according to the computational predictions. These 
predicted interactions then are compared with those observed in crystal structures of 
HIVP with the two inhibitors. Finally, the consequences of sulfonamide geometry on the 
docking predictions are analyzed.  
4.3.1 Computational design of combinatorial libraries 
Figure 4.2 shows how the distributions of the energy and Vout scores of the compounds 
under consideration changed during the design process, and elucidates the trade-off 
between the energy and Vout figures of merit.  The initial virtual library of ~3x109 
compounds, based upon all candidate substituents, has a mean docking energy of ~-30 
kcal/mol and a mean Vout of ~250 Å3 (solid black curve). Both of these values are 
approximations based upon reconstruction of the energies and volumes via the single-site 
Additivity approximation (Chapter 3) for 108 compounds randomly picked from the full 
virtual library.  Not surprisingly, better average docking and Vout scores, and narrower 
distributions, are observed for a smaller virtual library constructed from the 150 
substituents at each position that yielded the best combined docking and Vout Z-scores 
(dashed black curve).  
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The red and green distributions highlight the trade-off between selecting compounds 
according to docking score versus Vout. In both graphs, the red graph represents the 
distributions for the 100 compounds with the most favorable predicted docking scores: as 
expected, their docking scores are very low (top graph); but these compounds tend to be 
worse than the average compound in the 150x150x150 library (bottom graph). Thus, 
choosing compounds based purely on docking scores would not yield compounds that fit 
well into the substrate envelope.  Conversely, the green curves represent the distributions 
for the 100 compounds with the most favorable predicted values of Vout. These 
compounds fit the substrate envelope well (bottom graph), but have relatively poor 
docking scores (top graph).  
Finally, the blue curves in both graphs show the distributions of docking scores and Vout 
computed for the 26 compounds that were actually synthesized and tested. These data 
were obtained by docking each compound individually, rather than by applying the 
Additivity approximation.  It is evident that these compounds represent a compromise 
between optimization of docking scores alone (red graphs) and Vout alone (green) graphs, 
as the blue distributions peak between the red and green distributions. The docking scores 
of these compounds tend to be similar to that of Amprenavir (solid vertical line), while 












Figure 4.2: Distributions of docking energies (top) and volumes outside substrate 
envelope (Vout; bottom) computed for various compound sets.   
Solid black: 108 compounds drawn randomly from the full virtual library of ~3x109 
compounds; data estimated by single-site addtivity approximation.  Dashed black: all 
compounds constructed from the 150 candidate substituents at each position that gave 
optimal combined Z-scores (see 4.2.1.7); data estimated by single-site additivity 
approximation.  Red: 100 compounds with the best (lowest) docking scores estimated by 
single-site additivity.  Green: 100 compounds with the best (lowest) values of Vout 
estimated by single-site additivity.  Blue: 26 synthesized compounds; data computed by 
docking and scoring each of the 26 compounds.  Computed results for Amprenavir are 
indicated by vertical black lines. 
4.3.2 Binding affinity and resistance to mutation 
This work resulted in seven compounds with dissociation constants for wild-type HIVP 
in the nanomolar range, as shown in Table 4.1. For comparison, the table also provides 
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the structures of amprenavir, the smallest of the first-generation clinical inhibitors, and 
ritonavir, one of the largest, along with their measured dissociation constants.  The new 
compounds are similar in size to amprenavir. This is consistent with the use of fit to the 
substrate envelope as a design criterion, because smaller compounds tend to fit the 
substrate envelope better.   The two designed compounds of highest affinity, AD-37 and 
KB-45,  have low-nanomolar dissociation constants, but do not bind quite as tightly as 
amprenavir. 
 Compounds AD-37 and KB-45 were further tested against the panel of three mutant 
proteases, M1, M2 and M3, which are highly clinically relevant (as defined in Section 
2.2.3) according to the clinical relevance values listed in Table 4.2. The affinities of these 
two compounds for the three mutants are presented in Table 4.3, along with comparison 
data for a set of first-generation HIVP inhibitors in clinical use.  A graphical 
representation of the robustness of all the compounds is presented in Figure 4.3, using the 
definition provided in Section 2.2.2. Each line in Figure 4.3 represents one compound; 
and a lower, more level line indicates greater robustness to mutation.  By this measure, 
the two new compounds, AD-37 and KB-45, are more robust than any of the inhibitors 
except for amprenavir.  They also fit the substrate envelope better than any of the other 
inhibitors except for amprenavir, according to the values of Vout in Table 4.3.  However, 
it is important to note that the affinities of the new compounds are not especially good in 

















































































































































Table 4.1: Structures and inhibition constants, Ki ,for selected compounds.  
APV: amprenavir; RTV: ritonavir. The designed compounds were synthesized by Dr 
Akbar Ali and Dr Kiran Reddy. The enzyme inhibition experiments were conducted by 






M1 (D30N/L63P/N88D) 223 322 69.3 
M2 (L10I/G48V/I54V/L63P/ V82A)    14 75 18.7 
M3 













Table 4.2: Clinical relevance analysis of mutant proteases M1, M2 and M3. 




INHIBITORS VOUT (Å3) 
Wild-type M1 M2 M3 
AD37 155 23.90 62.90 358.4 371.70 
KB45 139 58.00 129.30 1288 2882.00 
Amprenavir 128 0.13 0.21 0.15 1.40 
Indinavir 180 0.18 0.73 33.58 21.15 
Saquinavir 213 0.07 1.03 89.53 78.44 
Nelfinavir 166 0.28 3.49 14.58 18.73 
Ritonavir 256 0.06 0.46 3.03 2.81 
Lopinavir 170 0.005 0.040 6.1 0.90 
Table 4.3: Measured inhibition constants Ki of designed compounds and first-
generation HIVP inhibitors. 
Vout: volume outside the substrate envelope, based upon crystal structures of the 
































Figure 4.3: Resistance profiles graphs. 
Gold: AD37. Blue: KB45. Bright green: Amprenavir. Red: Saquinavir, Indinavir, 
Nelfinavir, Ritonavir and Lopinavir.  
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4.3.3 Docked structures of inhibitor complexes 
Close interactions between HIVP and inhibitors AD37 and KB45 in their predicted poses 
are shown in Figures 4.4 and 4.5 respectively. The two compounds differ only at their R3 
substituent position, so it is not surprising that their interactions with HIV protease 
through the scaffold and other substituent sites are similar. The combinatorial scaffolds of 
both AD37 and KB45 form hydrogen bonds with the flap water and with residue Asp25, 
one of the catalytic aspartates (Figure 4.4a and 4.5a). The phenyl group of the scaffold 
and the cyclopropyl groups of both ligands are predicted to form nonpolar interactions at 
S1’ and S1 subsites of HIVP, respectively. The residues involved in these interactions are  
Pro81’ and Val82’ at the S1’ subsite, and Leu23 and Val82 at the S1 subsite (Figures 
4.4b, 4.4d, 4.5b and 4.5d).   
Crystal structures show that residues in the S2 and S2’ subsites of HIVP form both 
hydrophobic and hydrogen bonding interactions with existing inhibitors (31), and the 
docking calculations place the R1 and R3 substituent groups at the S2 and S2’ subsites, 
respectively. Even though the amide group of the R1 substituent is within hydrogen 
bonding distance of residues Asp29, Asp30 and Gly48 (Figures 4.4c and 4.5c), the angle 
is not optimal, so the interactions of the R1 substituent with the residues in S2 subsite are 
interpreted as mainly electrostatic in nature. Residue Asp30’ in the S2’ subsite is 
predicted to form a hydrogen bond with the R3 substituent of AD37. Otherwise, the R3 
substituents of both the ligands are predicted to form mainly nonpolar interactions with 
the protein.  In particular, Ala28 is predicted to be in hydrophobic contact with the m-
































Figure 4.4: Docked structure of AD37 with HIVP.  
(a) Hydrogen bonding interactions of the combinatorial scaffold. (b-e) Interactions of 
phenyl, R1, R2 and R3 substituents with the protease. Ligand and neighboring residues are 
shown in licorice model. The dotted lines represent non-bonded interactions between 































Figure 4.5: Docked structure of KB45 with HIVP. 
 (a) Hydrogen bonding interactions of the combinatorial scaffold. (b-e) Interactions of 
phenyl, R1, R2 and R3 substituents with the protease. 
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4.3.4 Crystal structures of HIV-1 protease complexes 
The crystallographic poses of AD-37 and KB-45 agree rather well with the predictions; 
the RMSD deviations of non-hydrogen atoms are 1.32 Å and 1.08 Å, respectively.  The 
observed interactions of these inhibitors with HIV-1 protease also are similar to the 
predictions, but some differences can be discerned by comparing Figure 4.4 with Figure 
4.6 and Figure 4.5 with Figure 4.7.  More schematic comparisons are presented in Figures 
4.8 and 4.9.  
The observed hydrogen bonding interactions between the scaffold and the flap water are 
as predicted, but the scaffold in the crystal structures forms one more hydrogen bond with 
Asp25’ than predicted: compare Figure 4.4a with Figure 4.6a and Figure 4.5a with Figure 
4.7a. The hydrophobic interactions of the scaffold’s phenyl group also are close to those 
observed in the docked poses, involving Pro81’, Val82’ and Gly49 in the S1’ subsite 
(Figures 4.4b vs. 4.6b and 4.5b vs. 4.7b).  However, the orientation and the interactions 
of the cyclopropyl group at R2 differ significantly from the predictions. In particular, the 
predicted nonpolar interaction with Leu23 at the S1 subsite is absent. The R1 substituents 
of both ligands form a hydrogen bond with backbone nitrogen of Asp29 at the S2 subsite, 
although this interaction was not observed in the most stable computed poses (Figures 
4.4c vs. 4.6c and 4.5c vs. 4.7c).   
The methoxy methyl moiety of the R3 substituent of AD-37 was predicted to form a 
nonpolar interaction with Val32 in the S2’ subsite, but the crystal structure instead shows 
multiple interactions between the benzene moiety of R3 and Val32.  Similarly, more 
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nonpolar interactions were observed than predicted between the R3 substituent of KB-45 
and nearby nonpolar groups (Figure 4.7e versus Figure 4.5e).   
Finally, the sulfonamide nitrogen in the crystal structures is inverted relative to that used 
in the docking calculations.  It was conjectured that this difference might account for 
differences between the predicted and observed positions of the various substituents.  The 






























Figure 4.6: Crystal structure of AD37 in complex with HIV-1 protease.  
(a) Hydrogen bonding interactions of the combinatorial scaffold. (b-e) Interactions of 
phenyl, R1, R2 and R3 substituents with the protease. The crystallographic analysis was 

































Figure 4.7: Crystal structure of KB45 in complex with HIV-1 protease.  
(a) Hydrogen bonding interactions of the combinatorial scaffold. (b-e) Interactions of 
phenyl, R1, R2 and R3 substituents with the protease. The crystallographic analysis was 






























































Figure 4.8: Interactions of AD-37 with the active site of HIV protease 





























































Figure 4.9: Interactions of KB-45 with the active site of HIV protease 




4.3.5 Consequences of sulfonamide geometry 
The geometry of the sulfonamide nitrogen could affect the VDock predictions directly by 
affecting the positioning of the substituents, and indirectly by affecting the protein 
conformation. The direct effect of the sulfonamide geometry was analyzed by additional 
docking calculations using AD-37 and KB-45 with both possible sulfonamide 
geometries. Possible indirect effects were examined by docking the ligands into two 
receptor structures, crystallized with ligands having different sulfonamide geometries, 
1HPV and KB60.  The four resulting docked conformations were superimposed and 
compared.  Tables 4.4 and 4.5 provide the RMSD of non-hydrogen atoms in the four 
docked conformations, relative to the crystal structure.  In all cases, docking with the 
inverted sulfonamide geometry of the crystal structures yielded lower RMSDs.  However, 
the choice of target protein structure has an inconsistent influence on the RMSD values: 
docking into KB60 gives lower RMSDs for AD-37, but higher RMSDs for KB-45.   
As shown in Figure 4.10, the conformation of the scaffold is similar across all four 
docked conformations of AD-37, so this aspect of the docked conformation is insensitive 
to sulfonamide geometry.  The scaffold of KB-45 is somewhat more sensitive to the 
sulfonamide geometry, as shown in Figure 4.11.   
The positioning of the cyclopropyl substituent at R2 overlays well on the crystal 
conformation only when the inverted sulfonamide geometry is used (two blue 
conformations in red regions of Figures 4.10 and 4.11); a significant discrepancy is 
observed when the 1HPV sulfonamide geometry is used (red and orange in Figures 4.10 
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and 4.11).  It is not surprising that the cyclopropyl group should be particularly sensitive 
to the sulfonamide geometry because it is linked directly to the nitrogen in question.  The 
R3  substituent also is bonded to the sulfonamide group and, like the cyclopropyl group, 
is best positioned when the inverted sulfonamide geometry of the crystal conformations is 
used during docking (two blue conformations in the red shaded regions of Figures 4.10 
and 4.11). The error in the predicted position of R3 of KB45 may result not only from the 
incorrect sulfonamide geometry, but also from its lack of strong interactions at the S2’ 
subsite, relative to AD-37 (Figures 4.10: red box vs. 4.11: red box), and hence greater 
mobility.   
Finally, the conformation of the R1 substituents of both AD37 and KB45 vary 
significantly among the docked poses, but no clear correlation is observed between the 
sulfonamide geometry options and the agreement with the crystal structures (Figures 4.10 














Figure 4.10: Superimposed docked structures of AD37. 
The R1 and the phenyl group of the scaffold are grouped together by a blue box and the 
R2 and R3 substituents by a red box, to highlight the variability within the docked poses. 
Predicted binding poses of AD37 with inverted sulfonamide geometry when docked into 
KB60 (blue) and 1HPV (ice blue); and AD37 with 1HPV like sulfonamide geometry 








1HPV 1HPV-like 1.32 
1HPV Inverted 0.90 
KB60 1HPV-like 0.73 
KB60 Inverted 0.65 
Table 4.4: RMSD between the corresponding non-hydrogen atoms in the docked 












Figure 4.11: Superimposed docked structures of KB45. 
The R1 and the phenyl group of the scaffold are grouped together by a blue box and the 
R2 and R3 substituents by a red box, to highlight the variability within the docked poses 
.at different substituent sites Predicted binding poses of KB45 with inverted sulfonamide 
geometry when docked into KB60 (blue) and 1HPV (ice blue); and KB45 with 1HPV 
















1HPV 1HPV-like 1.08 
1HPV Inverted 0.83 
KB60 1HPV-like 1.31 
KB60 Inverted 1.18 
Table 4.5: RMSD between the corresponding non-hydrogen atoms in the docked 






The present study provides a prospective evaluation of the substrate envelope hypothesis 
as a basis for the design of HIVP inhibitors with broad specificity against clinically 
relevant variants of HIV protease.  Incorporation of fit to the substrate envelope as a 
design criterion led to two new HIVP inhibitors of small size with relatively flat affinity 
profiles against a panel of clinically relevant mutants.  The volumes of the ligands lying 
outside the substrate envelope were computed from crystal structures of their complexes 
with HIVP, and were found to be less than those of all but one of the clinical inhibitors.  
These results support the validity of the hypothesis that compounds which fit within the 
envelope will resist mutations. It is worth mentioning that higher affinity compounds, 
with greater susceptibility to mutation, might have been chosen if the goal of achieving 
high affinity had not been partly balanced by the goal of fitting within the substrate 
envelope. 
Crystallographic studies of the new compounds AD37 and KB45 show generally good 
agreement between the predicted and crystal structures. However, the observed 
sulfonamide nitrogens are inverted relative to the conformation used in the design 
calculations.  Further docking calculations with the inverted geometry indicate that the R2 
and R3 substituents would have been more accurately positioned had the correct geometry 
been known in advance.  It is possible that repeating the full design procedure with the 
inverted geometry would lead to compounds of greater affinity than those identified here. 
More generally, the present results indicate that there might be considerable value in a 
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docking procedure that would automatically sample alternative geometries of invertible 
nitrogen atoms.  
Although the present results are encouraging, it is not expected that a relatively blunt 
instrument like the substrate envelope criterion will be fully reliable.  Utlimately, the 
subtleties of specific ligand-protein interactions will need to be considered.  Nonetheless, 
the substrate envelope method may be useful, especially given its convenient simplicity 
and the inexactness of current ligand scoring functions.  
4.5 Conclusions 
Inhibitors of HIVP that were computationally designed to stay within the consensus 
substrate volume were found to have favorable resistance profiles when tested against a 
panel of protease variants with clinically relevant mutations, although the affinities are 
not as great as those of current clinical inhibitors. This result supports the validity of the 
substrate envelope hypothesis.  
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Chapter 5. General Discussion 
Within approximately 15 years of the recognition of HIV protease as a viable target for 
AIDS, eight HIV protease inhibitors have been approved for the clinical use. The advent 
of these inhibitors greatly reduced the morbidity and mortality rate in AIDS patients. But 
unfortunately, the prevalence of treatment resistant strains has been observed to quickly 
rise within few years of treatment initiation(132).  This rapid development of resistant 
strains is a major challenge in the AIDS therapy. 
The main goal of our work was to develop and test an approach to the computational 
design of HIV protease inhibitors with minimal susceptibility to treatment resistant 
mutations. This project poses three major challenges: devising a computable quantity that 
might correlate with the robustness of an inhibitor against mutations; development of a 
efficient method of handling the combinatorial problem of library design; and selection of 
a scoring function or energy model that might be predictive of ligand affinity. The 
following paragraphs present a brief discussion of these challenges, our experience with 
them, and their possible or partial solution.  
5.1 Design strategy 
There are several workable strategies for the design of mutation resistant inhibitors. One 
is to design inhibitors that remain within the consensus substrate volume. This strategy is 
based on the observation that the primary active site resistance mutations occur at sites 
which are essential for inhibitor, but not substrate, recognition. We devised a quantitative 
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measure of the fit of a candidate ligand to the substrate envelope and observed a 
correlation between it the observed clinical resistance. This result justified using it in our 
design of a combinatorial library of inhibitors, which yielded inhibitors with nanomolar 
affinity and good resistance profiles. As this simple method is not expected to be 
infallible, designed compounds could also be evaluated against other criteria and selected 
based upon a consensus scoring scheme.   
Another approach would be to design compounds with high predicted affinity for the 
wild type protease and also for a panel of specific protease variants with clinically 
observed mutations (60). HIV-2 protease also could be used in place of a mutant HIV-1 
protease, because it differs from HIV-1 protease at the residues that are prone to mutate 
(133). This approach requires docking and scoring of compounds into multiple similar 
protein structures. Because an efficient method of serial docking of ligands into multiple 
target structures has already been implemented and tested in our lab (134), it would fairly 
straightforward to use this approach to seek compounds with broad specificity. Other 
serial docking methods, such as the one studied by Lamb etal can also be used for this 
purpose (135).  
Inhibitors could also be designed to interact only with main chain atoms and the 
conserved residues of the HIV protease. This approach is based on the observation that 
the overall shape of this protein remains constant in spite of differences in the substrates 
and ligands that bind it (31). This design method also would be easy to implement with 
our grid-based scoring function. Grids that store interaction potentials of only the main 
chain atoms and conserved residues can be readily generated by using a modified HIV 
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protease, in which residues other than the conserved ones are replaced by alanine 
residues.  
Finally, inhibitors that target nonstandard sites, such as the dimerization region or the 
open conformation of the active site, are also potential drug candidates to avoid resistance 
(132). Compound databases and combinatorial libraries can readily be screened against 
such targets.  
5.2 Combinatorial library design 
With the advent of automation technologies and high throughput screening, today’s 
medicinal chemistry has enormous potential to yield drug leads. However, it still is not 
possible to synthesize and screen the billions and trillions of compounds that could in 
principle be built from a combinatorial scaffold and ever-expanding libraries of building 
blocks (77). Hence computational techniques are needed to guide selecting of a 
sublibrary of compounds for synthesis and testing. There are several virtual screening 
methods available for this purpose. Among them, structure-based drug design has been 
shown to have higher predictability and more efficiency (65), but such methods are 
computationally more expensive than other virtual screening methods. Even if it takes 
less than a minute to screen a compound, it could take years to screen a huge 
combinatorial library of compounds. This problem can be addressed by several 
optimization methods, such as simulated annealing and genetic algorithms. Alternatively, 
selection of substituents independently for each substituent position can make the 
combinatorial problem a linear one and circumvent the combinatorial explosion. This 
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approach is based on the assumption that there will be little or no interaction between the 
substituents at different substituent positions.  
We have evaluated this simple additivity method and used it in the selection of 
sublibraries of compounds from virtual combinatorial libraries of 3 billion compounds. 
Interestingly, the additivity method in general worked as well as the GA method. 
However, the assumption of additivity can break down under certain conditions, such as 
when a combinatorial scaffold has excessive conformational freedom, or when 
substituents contact each other. In our HIVP test system, the combinatorial scaffold has 
key interactions with the target protein which anchor it in the active site, and the crystal 
structure of a compound with this scaffold bound to HIVP confirms the validity of the 
positioning of the scaffold. This situation allowed reasonable restrictions to be placed on 
movement of the scaffold during the docking calculations. These restrictions also helped  
speed the calculations.  
In some cases, one may not have prior information on the scaffold position. The literature 
suggests several computational approaches to this situation.  The binding pose can be 
determined by docking compounds that share the same combinatorial scaffold (136), 
which can be obtained from the literature (136) or by building a few combinatorial 
compounds using methyl groups or diverse functional groups as substituents, or by using 
substituents that are common to the class of compounds that was studied (137). The 
consensus binding pose of the scaffold in all the docked poses of the screened compounds 
can then be selected for use in the additivity method.  There is also one report that 
mentions the use of a bare scaffold (77), to obtain the binding pose. It would also be 
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possible to use a GA for this purpose, with the expectation that the top scoring 
compounds from the final generation will have only a few distinct binding poses. The 
efficiency of the GA for this purpose can be further enhanced by limiting cross-over to 
the segments that are proximal in the active site.   
The GA is a versatile optimization method which could be further tuned for 
combinatorial library design. For example, mutation operations could be biased in favor 
of choosing substituents that are chemically similar to moieties of a known ligand, or in 
favor of choosing substituents with chemotypes that have not yet been tested during the 
current GA run.  Mutations could also be biased to choose substituents that score highly 
in single-site Additivity calculations, thus blending the Additivity and GA approaches. 
The fitness function can also be tuned for specific purposes, much as we combined the 
docking energy with the substrate envelope criterion by using Z-scores to combine fitness 
measures with different units.  Other methods such as Pareto ranking can also be used to 
combine multiple objectives (70). 
There are some preliminary filters that can also be used to increase the efficiency of 
combinatorial library design. For example, substituent libraries can be preselected to 
eliminate compounds with more than one functional group that can react in the selected 
combinatorial synthetic scheme, in order to generate designed compounds that avoid 
synthetic pitfalls. Subtituent libraries can also be sorted or filtered based on cost and 
availability, or enriched with the bio-isosteres or with the substituents from other 
compounds known to bind the protein target (137, 138). As the availability and binding 
affinity of these substituents to a similar target protein are already known, this approach 
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in the selection of substituent library will appeal to the medicinal chemists tasked with 
synthesizing the designed libraries. 
Lipinski’s “rule of five” (139) , which seeks to differentiate drug-like compounds from 
others based on simple physical properties (molecular weight, number of hydrogen bond 
donors, acceptors and partition coefficient) can also be used as a preliminary filter to 
eliminate non-drug-like compounds from the combinatorial library before screening them 
with more computationally intensive docking and scoring functions. Other ligand-based 
virtual screening methods can also be used for pruning the huge combinatorial search 
space.   
5.3 Docking and scoring functions 
Even though docking and scoring functions are considered more reliable than ligand-
based virtual screening methods, they have their own limitations. For example, they make 
gross approximations regarding the flexibility of the protein, or lack thereof,  and in the 
treatment of solvent effects. These approximations severely limit the predictivity of 
affinity calculations, and a high level of accuracy is not routinely achievable (140). It is 
important for the user to be aware of the limitations of current docking and scoring 
methods, and to interpret their results in the light of the approximations they make. In 
spite of all these limitations, these methods can still contribute significantly to drug 
discovery.  
Our in-house docking and scoring function, VDock led to several low nanomolar 
inhibitors with good resistance profiles. It is worth noting that the compounds were 
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optimized not only for their docking energy scores, but also for their fit to the substrate 
envelope; compounds with higher affinity for the wild-type protease might have been 
discovered if the substrate envelope criterion had not been applied. Nonetheless, our 
energy scores correlated poorly with measured affinity (data not shown), so there is 
clearly much room for improvement. Prediction of binding energies is still a daunting 
task in the field of virtual screening.  
As mentioned above, one source of error probably is the imprecise treatment of solvent 
effects. For example, VDock does not impose an energy penalty for removing a polar 
moiety from solvent upon binding. It might be possible to overcome this limitation, at 
least in part, by penalizing bound conformations with unsatisfied hydrogen bonding 
donors and acceptors groups. This would avoid the unfavorable placement of nonpolar 
groups next to polar groups. It might also be possible to include a limited number of 
explicit water molecules while docking candidate ligands. These would probably need to 
have rather limited freedom of movement to avoid computationally intensive 
calculations. Such water molecules could be restricted to locations where there is 
sufficient space to accommodate a water molecule and where there are unsatisfied 
hydrogen bonds in both the ligand and the receptor. Identification of such spots may 
require preliminary docking runs without water molecules, followed by a second set of 
docking runs with localized water molecules.. 
Another major missing element in scoring functions is change in configurational entropy 
on binding. This is often approximated based upon the number of rotatable bonds in the 
ligand, but recent calculations in our group suggest that such approaches are not well-
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founded physically and markedly underestimate the entropy penalty. Ongoing research 
the group may lead to better approximations for this missing term.  
It seems likely that improving the treatment of solvent and of configurational entropy will 
significantly improve the accuracy of docking and scoring calculations. Further 
improvement may be gained by combining multiple, complementary scoring functions, 
rather than relying upon just one. Such “consensus scoring” methods have been shown to 
significantly improve the yield of ligands in structure-based drug design  (141). 
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Chapter 6. Conclusions 
This thesis has described the design of HIV protease inhibitors with broad specificity. 
The main contributions are as follows: (1) A method to quantify the fit of a compound to 
the substrate envelope has been developed and evaluated, both retrospectively and 
prospectively. The method can be easily used in virtual high throughput docking and the 
design of combinatorial libraries. (2) A novel criterion for the clinical relevance of HIV 
protease mutations has been put forward. (3) A fast, simple Additivity method for the 
structure-based design of combinatorial libraries has been implemented, evaluated, 
employed in a real-world design project. (4) A Genetic Algorithm has also been 
developed for combinatorial library design. This can be useful for systems for which the 
Additivity method is not expected to be applicable. (5) Our work resulted in two low 
nanomolar compounds with favorable resistance profiles against a panel of clinically 
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